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A B S T R A C T
Background
Approximately 2.5% of all hospitalisations in people with cirrhosis are for spontaneous bacterial peritonitis (SBP). Antibiotics, in addition
to supportive treatment (fluid and electrolyte balance, treatment of shock), form the mainstay treatments of SBP. Various antibiotics are
available for the treatment of SBP, but there is uncertainty regarding the best antibiotic for SBP.
Objectives
To compare the benefits and harms of different antibiotic treatments for spontaneous bacterial peritonitis (SBP) in people with decom-
pensated liver cirrhosis.
Search methods
We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Reg-
istry Platform, and trials registers until November 2018 to identify randomised clinical trials on people with cirrhosis and SBP.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in adults with cirrhosis and SBP. We
excluded randomised clinical trials in which participants had previously undergone liver transplantation.
Data collection and analysis
Two review authors independently identified eligible trials and collected data. The outcomes for this review included mortality, serious
adverse events, any adverse events, resolution of SBP, liver transplantation, and other decompensation events. We performed a network
meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio with 95% credible inter-
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vals (CrIs) based on an available-case analysis, according to the National Institute of Health and Care Excellence (NICE) Decision Support
Unit guidance.
Main results
We included a total of 12 trials (1278 participants; 13 antibiotics) in the review. Ten trials (893 participants) were included in one or more
outcomes in the review. The trials that provided the information included patients having cirrhosis with or without other features of de-
compensation of varied aetiologies. The follow-up in the trials ranged from one week to three months. All the trials were at high risk of
bias. Only one trial was included under each comparison for most of the outcomes. Because of these reasons, there is very low certainty
in all the results. The majority of the randomised clinical trials used third-generation cephalosporins, such as intravenous ceftriaxone,
cefotaxime, or ciprofloxacin as one of the interventions.
Overall, approximately 75% of trial participants recovered from SBP and 25% of people died within three months. There was no evidence
of difference in any of the outcomes for which network meta-analysis was possible: mortality (9 trials; 653 participants), proportion of
people with any adverse events (5 trials; 297 participants), resolution of SBP (as per standard definition, 9 trials; 873 participants), or other
features of decompensation (6 trials; 535 participants). The effect estimates in the direct comparisons (when available) were very similar to
those of network meta-analysis. For the comparisons where network meta-analysis was not possible, there was no evidence of difference
in any of the outcomes (proportion of participants with serious adverse events, number of adverse events, and proportion of participants
requiring liver transplantation). Due to the wide CrIs and the very low-certainty evidence for all the outcomes, significant benefits or harms
of antibiotics are possible.
None of the trials reported health-related quality of life, number of serious adverse events, or symptomatic recovery from SBP.
Funding: the source of funding for two trials were industrial organisations who would benefit from the results of the trial; the source of
funding for the remaining 10 trials was unclear.
Authors' conclusions
Short-term mortality after SBP is about 25%. There is significant uncertainty about which antibiotic therapy is better in people with SBP.
We need adequately powered randomised clinical trials, with adequate blinding, avoiding post-randomisation dropouts (or performing
intention-to-treat analysis), and using clinically important outcomes, such as mortality, health-related quality of life, and adverse events.
P L A I N   L A N G U A G E   S U M M A R Y
Antibiotic treatment for spontaneous bacterial peritonitis in people with advanced liver disease
What is the aim of this Cochrane Review?
To find out the best available antibiotic for spontaneous bacterial peritonitis (fluid collection in the tummy (abdomen), infected with bac-
teria) in people with advanced liver disease (liver cirrhosis, or late stage scarring of the liver with complications). The abnormal buildup
of fluid in people with liver cirrhosis is called ascites. Sometimes, this fluid may get infected with bacteria, with no obvious source of in-
fection. This is called 'spontaneous bacterial peritonitis'. The main treatment of spontaneous bacterial peritonitis is antibiotics, but it is
unclear which antibiotic is best for treating it. The authors collected and analysed all relevant studies to answer this question and found 12
randomised clinical trials (participants receive the treatment based on methods similar to a coin toss; this is to ensure that the people who
receive the different treatments are similar in all aspects except the treatment, so that any differences in the results between the treat-
ments can be attributed to the treatment rather than differences in the type of people who received the treatment). During the analysis
of data, authors used standard Cochrane techniques, which allows comparison of two treatments at a time. Authors also used advanced
techniques, that allows comparison of many treatments at the same time (usually referred as 'network meta-analysis' or 'multiple treat-
ment comparisons'). The aim is to gather reliable evidence on the relative benefits and harms of the different antibiotics.
Date of literature search
November 2018.
Key messages
None of the studies were conducted without flaws, and because of the very low certainty in the results, the authors cannot suggest which
antibiotic, given alone or in combination to remove the bacteria from one's tummy, is better or worse than other antibiotics in the treat-
ment of spontaneous bacterial peritonitis.
The funding source was unclear in 10 studies; industrial organisations funded two studies.
What was studied in the review?
This review studied people, of any sex, age, and origin, with advanced liver disease due to various causes, and who had developed spon-
taneous bacterial peritonitis. People were administered different antibiotics for the treatment of spontaneous bacterial peritonitis. The
authors excluded studies with liver transplanted participants and bacterial peritonitis due to other causes. The participants' age, when
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reported, ranged from 42 to 60 years. The number of females, when reported, ranged from 18 to 42 out of 100. The administered antibiot-
ic groups were cephalosporins, penicillins, and quinolones. The review authors wanted to gather and analyse data on death, quality of
life, serious and non-serious complications, time to liver transplantation (replacement of a diseased liver with a healthy one), time until
disappearance of spontaneous bacterial peritonitis, and disappearance of symptoms.
What were the main results of the review?
The 12 studies included a small number of participants (1278 participants). The study data were sparse; 10 studies with 893 participants
provided data for analyses. Follow-up in the trials ranged from one week to three months. The review shows the following.
- Out of the 13 different antibiotics compared in the trials, ceftriaxone and cefotaxime administered into the vein, were most commonly
used.
- The type of antibiotic provided may make no difference to the number or percentage of people with serious complications or with any
complications; number of (any) complications per person; percentage of people undergoing liver transplantation; or who recovered from
spontaneous bacterial peritonitis as per laboratory tests, or other complications of liver cirrhosis.
- Twenty-five out of every 100 people died within three months, and 75 out of every 100 people recovered from spontaneous bacterial
peritonitis.
- None of the trials reported health-related quality of life, number of serious adverse events, or symptomatic recovery from spontaneous
bacterial peritonitis.
- We have very low confidence in the overall results. Whether some antibiotics may cause important or less important benefits or harms
compared to others when given to people with advanced liver disease and spontaneous bacterial peritonitis is questionable.
- We need data from trials of proper design and quality in order to be able to clarify the best antibiotic for spontaneous bacterial peritonitis.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis
Patient or population: people with cirrhosis and spontaneous bacterial peritonitis
Settings: secondary or tertiary care
Intervention: various interventions
Comparison: ceftriaxone
Follow-up period: 1 week to 3 months
Network geometry plots: Figure 1
Anticipated absolute effect* (95% CrI)Interventions Relative effect
(95% CrI)
Ceftriaxone Various interventions Difference
Certainty of
evidence
Ranking**
All-cause mortality
Total studies: 7
Total participants: 458
Cefotaxime
(1 RCT; 37 participants)
HR 0.56
(0.11 to 2.28)
Network estimate
263 per 1000 146 per 1000
(28 to 599)
117 fewer per 1000
(235 fewer to 336 more)
Very lowa,b,c -
Ciprofloxacin
(1 RCT; 35 participants)
HR 0.65
(0.12 to 2.72)
Network estimate
263 per 1000 171 per 1000
(31 to 717)
92 fewer per 1000
(232 fewer to 454 more)
Very lowa,b,c -
Ceftazidime
(No direct RCT)
HR 1.15
(0.17 to 6.37)
Network estimate
263 per 1000 301 per 1000
(45 to 1000)
38 more per 1000
(218 fewer to 737 more)
Very lowa,b,c -
Amikacin
(No direct RCT)
HR 0.76
(0.09 to 5.90)
Network estimate
263 per 1000 201 per 1000
(24 to 1000)
62 fewer per 1000
(239 fewer to 737 more)
Very lowa,b,c -
Cefixime
(1 RCT; 38 participants)
HR 1.26
(0.26 to 6.90)
Network estimate
263 per 1000 331 per 1000
(68 to 1000)
68 more per 1000
(195 fewer to 737 more)
Very lowa,b,c -
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Cefonicid
(1 RCT; 60 participants)
HR 1.30
(0.52 to 3.24)
Network estimate
263 per 1000 341 per 1000
(138 to 853)
78 more per 1000
(126 fewer to 590 more)
Very lowa,b,c -
Meropenem plus dapto-
mycin
(No direct RCT)
HR 0.64
(0.05 to 6.13)
Network estimate
263 per 1000 169 per 1000
(14 to 1000)
94 fewer per 1000
(249 fewer to 737 more)
Very lowa,b,c -
Ofloxacin
(No direct RCT)
HR 0.56
(0.09 to 2.93)
Network estimate
263 per 1000 147 per 1000
(23 to 770)
116 fewer per 1000
(240 fewer to 507 more)
Very lowa,b,c -
Health-related quality of life
None of the trials reported this outcome
Serious adverse events (proportion of participants)
None of the trials with ceftriaxone as control group reported this outcome
Serious adverse events (number of events per participant)
None of the trials reported this outcome
Adverse events (proportion of participants)
Total studies: 5
Total participants: 297
Cefotaxime
(1 RCT; 37 participants)
OR 0.64
(0.15 to 2.62)
Network estimate
67 per 1000 44 per 1000
(10 to 157)
23 fewer per 1000
(56 fewer to 91 more)
Very lowa,b,c -
Ciprofloxacin
(1 RCT; 35 participants)
OR 1.02
(0.24 to 4.16)
Network estimate
67 per 1000 68 per 1000
(17 to 229)
1 more per 1000
(50 fewer to 162 more)
Very lowa,b,c -
Ceftazidime
(No direct RCT)
OR 1.97
(0.38 to 10.18)
Network estimate
67 per 1000 123 per 1000
(27 to 421)
57 more per 1000
(40 fewer to 354 more)
Very lowa,b,c -
Amikacin
(No direct RCT)
OR 0.69
(0.04 to 10.94)
Network estimate
67 per 1000 47 per 1000
(3 to 439)
20 fewer per 1000
(64 fewer to 372 more)
Very lowa,b,c -
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Cefonicid
(1 RCT; 60 participants)
OR 1.00
(0.10 to 10.16)
Network estimate
67 per 1000 67 per 1000
(7 to 420)
0 fewer per 1000
(60 fewer to 354 more)
Very lowa,b,c -
Meropenem plus dapto-
mycin
(No direct RCT)
OR 1.20
(0.10 to 13.53)
Network estimate
67 per 1000 79 per 1000
(7 to 491)
12 more per 1000
(60 fewer to 425 more)
Very lowa,b,c -
Adverse events (number of events per participant)
None of the trials with ceftriaxone as control group reported this outcome
Liver transplantation
None of the trials with ceftriaxone as control group reported this outcome
Spontaneous bacterial peritonitis (symptomatic)
None of the trials reported this outcome
Spontaneous bacterial peritonitis (as per definition used for spontaneous bacterial peritonitis)
Total studies: 7
Total participants: 638
Cefotaxime
(1 RCT; 37 participants)
HR 0.90
(0.42 to 1.86)
Network estimate
733 per 1000 661 per 1000
(308 to 1000)
73 fewer per 1000
(425 fewer to 267 more)
Very lowa,b,c -
Ciprofloxacin
(2 RCT; 275 participants)
HR 0.93
(0.69 to 1.25)
Network estimate
733 per 1000 679 per 1000
(504 to 916)
54 fewer per 1000
(230 fewer to 183 more)
Very lowa,b,c -
Ceftazidime
(No direct RCT)
HR 0.97
(0.55 to 1.72)
Network estimate
733 per 1000 713 per 1000
(403 to 1000)
21 fewer per 1000
(330 fewer to 267 more)
Very lowa,b,c -
Amikacin
(No direct RCT)
HR 0.54
(0.17 to 1.62)
Network estimate
733 per 1000 393 per 1000
(126 to 1000)
340 fewer per 1000
(608 fewer to 267 more)
Very lowa,b,c -
Cefixime
(1 RCT; 38 participants)
HR 0.78
(0.32 to 1.90)
Network estimate
733 per 1000 575 per 1000
(232 to 1000)
159 fewer per 1000
(501 fewer to 267 more)
Very lowa,b,c -
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Meropenem plus dapto-
mycin
(No direct RCT)
HR 1.29
(0.43 to 3.92)
Network estimate
733 per 1000 944 per 1000
(315 to 1000)
211 more per 1000
(419 fewer to 267 more)
Very lowa,b,c -
Ofloxacin
(No direct RCT)
HR 1.12
(0.45 to 2.70)
Network estimate
733 per 1000 825 per 1000
(330 to 1000)
91 more per 1000
(404 fewer to 267 more)
Very lowa,b,c -
Other features of decompensation (per participant)
Total studies: 5
Total participants: 360
Cefotaxime
(1 RCT; 37 participants)
Rate ratio 1.22
(0.43 to 3.53)
Network estimate
368 per 1000 449 per 1000
(160 to 1301)
80 more per 1000
(209 fewer to 933 more)
Very lowa,b,c -
Ciprofloxacin
(1 RCT; 35 participants)
Rate ratio 1.01
(0.32 to 3.16)
Network estimate
368 per 1000 373 per 1000
(119 to 1164)
4 more per 1000
(249 fewer to 795 more)
Very lowa,b,c -
Ceftazidime
(No direct RCT)
Rate ratio 1.43
(0.40 to 5.19)
Network estimate
368 per 1000 527 per 1000
(147 to 1911)
159 more per 1000
(222 fewer to 1542 more)
Very lowa,b,c -
Amikacin
(No direct RCT)
Rate ratio 1.28
(0.11 to 15.66)
Network estimate
368 per 1000 471 per 1000
(40 to 5769)
103 more per 1000
(329 fewer to 5400 more)
Very lowa,b,c -
Meropenem plus dapto-
mycin
(No direct RCT)
Rate ratio 2.19
(0.49 to 9.49)
Network estimate
368 per 1000 807 per 1000
(179 to 3495)
438 more per 1000
(189 fewer to 3127 more)
Very lowa,b,c -
Ofloxacin
(No direct RCT)
Rate ratio 1.12
(0.31 to 4.09)
Network estimate
368 per 1000 412 per 1000
(113 to 1508)
44 more per 1000
(255 fewer to 1139 more)
Very lowa,b,c -
*Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the weighted me-
dian risk of the control group.
**Ranking is not provided as the median rank was not 1 for at least one of the ranking positions for each intervention for the outcome.
CrI: credible interval; HR: hazard ratio; OR: odds ratio; RCT: randomised clinical trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
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Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aThe trial(s) included in the analysis was/were at high risk of bias (downgraded 1 level).
bThe sample size was small (downgraded 1 level).
cThe credible intervals were wide (includes clinical benefit and harms) (downgraded 1 level).
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Figure 1.   The network plots showing the outcomes for which network meta-analysis was performed. The size of the node (circle) provides a measure
of the number of trials in which the particular intervention was included as one of the intervention groups. The thickness of the line provides a
measure of the number of direct comparisons between two nodes (interventions). C
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Summary of findings 2.
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis
Patient or population: people with cirrhosis and spontaneous bacterial peritonitis
Settings: secondary or tertiary care
Intervention: various interventions
Comparison: ceftriaxone
Follow-up period: 1 week to 3 months
Network geometry plots: Figure 1
Outcomes Cefotaxime Ciprofloxacin
All-cause mortality
Ceftriaxone
263 per 1000
(26.3%)
HR 0.56
(0.11 to 2.28)
Network estimate
117 fewer per 1000
(235 fewer to 336 more)
HR 0.65
(0.12 to 2.72)
Network estimate
92 fewer per 1000
(232 fewer to 454 more)
  Very low1,2,3 Very low1,2,3
Rank*: - Rank: - Rank: -
  Based on 37 participants (1 RCT) Based on 35 participants (1 RCT)
Adverse events (proportion of participants)
Ceftriaxone
67 per 1000
(6.7%)
OR 0.64
(0.15 to 2.62)
Network estimate
23 fewer per 1000
(56 fewer to 91 more)
OR 1.02
(0.24 to 4.16)
Network estimate
1 more per 1000
(50 fewer to 162 more)
  Very low1,2,3 Very low1,2,3
Rank: - Rank: - Rank: -
  Based on 37 participants (1 RCT) Based on 35 participants (1 RCT)
Spontaneous bacterial peritonitis (as per definition used for spontaneous bacterial peritonitis)
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Ceftriaxone
733 per 1000
(73.3%)
HR 0.90
(0.42 to 1.86)
Network estimate
73 fewer per 1000
(425 fewer to 267 more)
HR 0.93
(0.69 to 1.25)
Network estimate
54 fewer per 1000
(230 fewer to 183 more)
  Very low1,2,3 Very low1,2,3
Rank: - Rank: - Rank: -
  Based on 37 participants (1 RCT) Based on 275 participants (2 RCT)
Other features of decompensation (per participant)
Ceftriaxone
368 per 1000
(36.8 per 100 partici-
pants)
Rate ratio 1.22
(0.43 to 3.53)
Network estimate
80 more per 1000
(209 fewer to 933 more)
Rate ratio 1.01
(0.32 to 3.16)
Network estimate
4 more per 1000
(249 fewer to 795 more)
  Very low1,2,3 Very low1,2,3
Rank: - Rank: - Rank: -
  Based on 37 participants (1 RCT) Based on 35 participants (1 RCT)
*Ranking is not provided as the median rank was not 1 for at least one of the ranking positions for each intervention for the outcome.
CrI: credible interval; HR: hazard ratio; OR: odds ratio; RCT: randomised clinical trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aThe trial(s) included in the analysis was/were at high risk of bias (downgraded one level).
bThe sample size was small (downgraded one level).
cThe credible intervals were wide (includes clinical benefit and harms) (downgraded one level).
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B A C K G R O U N D
Description of the condition
Liver cirrhosis
The liver is a complex organ with multiple functions, including me-
tabolism of carbohydrates, fats, proteins, and drugs; it also has syn-
thetic, storage, digestive, excretory, and immunological functions
(Read 1972). Liver cirrhosis is a liver disease in which the normal mi-
crocirculation, the gross vascular anatomy, and the hepatic archi-
tecture have been variably destroyed and altered, with fibrous sep-
ta surrounding regenerated or regenerating parenchymal nodules
(Tsochatzis 2014; NCBI 2018a). The major causes of liver cirrhosis
include excessive alcohol consumption, viral hepatitis, non-alco-
hol-related fatty liver disease, autoimmune liver disease, and meta-
bolic liver disease (Williams 2014; Ratib 2015; Setiawan 2016). The
global prevalence of liver cirrhosis is difficult to estimate as most
estimates correspond to chronic liver disease (which includes liver
fibrosis and liver cirrhosis). In studies from the USA, the prevalence
of chronic liver disease varies between 0.3% and 2.1% (Scaglione
2015; Setiawan 2016); in the UK, the prevalence was 0.1% in one
study (Fleming 2008). In 2010, liver cirrhosis caused an estimated
2% of all global deaths, equivalent to one million deaths (Mokdad
2014). There is an increasing trend of cirrhosis-related deaths in
some countries, like the UK, while there is a decreasing trend in
other countries, for example France (Mokdad 2014; Williams 2014).
The major cause of complications and deaths in people with liver
cirrhosis is due to the development of clinically significant portal
hypertension - hepatic venous pressure gradient at least 10 mmHg
(de Franchis 2015). Some of the clinical features of decompensa-
tion include jaundice, coagulopathy, ascites, variceal bleeding, he-
patic encephalopathy, and renal failure (de Franchis 2015; McPher-
son 2016; EASL 2018). Decompensated cirrhosis is the most com-
mon indication for liver transplantation (Merion 2010; Adam 2012).
Spontaneous bacterial peritonitis (SBP)
Ascites is accumulation of free fluid in the abdomen (peritoneal
cavity) (NCBI 2018b), and is a feature of liver decompensation
(Tsochatzis 2017; EASL 2018). Approximately 20% of people with
cirrhosis have ascites (D'Amico 2014). Approximately 1% to 4%
of people with cirrhosis develop ascites each year (D'Amico 2006;
D'Amico 2014). Ascites is the first sign of liver decompensation in
about one-third of people with compensated liver cirrhosis (D'Am-
ico 2014). When the ascitic fluid is infected with bacteria, it is called
'spontaneous bacterial peritonitis' (SBP). Due to the poor sensitivi-
ty of ascitic fluid culture, SBP is diagnosed by a polymorphonuclear
(PMN) leukocyte count of more than 250 per mm3 in the ascitic fluid
(Rimola 2000; EASL 2018). In the presence of haemorrhagic ascites
(ascites with red blood cell count of more than 10,000 per mm3),
one PMN leukocyte count should be subtracted for every 250 red
blood cells to account for the presence of blood in the ascitic fluid
(Rimola 2000). People with SBP may or may not display symptoms
of peritonitis, such as abdominal pain fever,chills, and hypotension
(Rimola 2000; Nousbaum 2007; EASL 2010).
The overall incidence and prevalence of SBP in people with cir-
rhosis is difficult to estimate. Approximately 2.5% of all hospital-
isations in people with cirrhosis are for SBP (Devani 2017). The
prevalence of SBP in patients with cirrhosis and ascites undergoing
paracentesis varies from 0.5% to 8.7% (Nousbaum 2007; Castellote
2008; Khan 2009; Cadranel 2013). The incidence of SBP in people
with decompensated liver cirrhosis is about 20% over a period of
one to 12 months (Saab 2009).
The short-term mortality (that is, death within 30 days of diagno-
sis or death in hospital) after SBP is about 15% to 40% (Khan 2009;
Tandon 2011; Devani 2017). In addition, SBP is associated with sig-
nificant resource utilisation; a study conducted in the USA showed
that the average length of hospital stay was approximately six days
and the average hospital costs per patient were approximately USD
17,000 (Devani 2017).
Pathophysiology of SBP
Increased bacterial translocation (gut bacteria or bacterial prod-
ucts migrating outside the intestinal lumen) and decreased local
and systemic immune responses in patients having cirrhosis are be-
lieved to be the cause of SBP (Bernardi 2010).
Description of the intervention
Antibiotics, in addition to supportive treatment (fluid and elec-
trolyte balance, treatment of shock) form the mainstay treatment
of SBP. There are various classes of antibiotics available for the
treatment of SBP. If bacteria can be cultured from the ascitic fluid,
antibiotic therapy can be based on the susceptibility of the bacteria
to different antibiotics (EASL 2010; Runyon 2013; EASL 2018). How-
ever, bacteria can be cultured only in 40% to 60% of people with
SBP (Rimola 2000; EASL 2010). Therefore, empirical antibiotic treat-
ment is used in the majority of people with SBP (EASL 2010; Runyon
2013; EASL 2018). The major classes of empirical antibiotics used
in the treatment of SBP include third-generation cephalosporins,
such as ceftriaxone, cefotaxime, and - less commonly - penicillins,
such as amoxicillin/clavulanic acid, and fluoroquinolones, such as
ciprofloxacin (in people who have not taken fluoroquinolones for
prophylaxis of SBP) (EASL 2010; Runyon 2013; EASL 2018).
How the intervention might work
Different antibiotic classes have different mechanisms of action to
kill bacteria (bactericidal effect) or reduce their growth (bacterio-
static effect). Penicillins and cephalosporins inhibit bacterial cell
wall synthesis (Yocum 1980; Yotsuji 1988). Fluoroquinolones are
type II topoisomerase inhibitors; type II topoisomerases at appro-
priate levels are required for normal cellular processes, and alter-
ing their levels leads to bacterial cell death (Aldred 2014). Other an-
tibiotics act via bacteriostatic effects.
Why it is important to do this review
SBP is associated with significant short-term mortality (Khan 2009;
Tandon 2011; Devani 2017). It is important to provide optimal em-
pirical treatment to people with SBP while waiting for the results
of ascitic fluid culture and sensitivity (susceptibility of bacteria to
the specific antibiotic) to improve their survival. Bacteria can be
cultured only in 40% to 60% of people with SBP (Rimola 2000;
EASL 2010). Several different antibiotic treatments are available,
but their relative efficacy and the optimal combination are not
known. There has been one Cochrane Review on the role of antibi-
otics in patients with cirrhosis and SBP (Chavez-Tapia 2009); how-
ever, there have been no previous network meta-analyses on the
topic. Network meta-analysis allows for a combination of direct
and indirect evidence, and the ranking of different interventions for
different outcomes (Salanti 2011; Salanti 2012). With this system-
atic review and network meta-analysis, we aim to provide the best
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis
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level of evidence for the benefits and harms of different antibiotic
treatments for SBP in people with decompensated liver cirrhosis.
O B J E C T I V E S
To compare the benefits and harms of different antibiotic treat-
ments for spontaneous bacterial peritonitis (SBP) in people with
decompensated liver cirrhosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for this network
meta-analysis, irrespective of language, publication status, or date
of publication. We excluded studies with a quasi-randomised de-
sign or non-randomised design because of the risk of bias in such
studies. Inclusion of indirect observational evidence could weak-
en our network meta-analysis, but this could also be viewed as a
strength for assessing rare adverse events. It is well established
that exclusion of non-randomised studies increases the focus on
potential benefits and reduces the focus on the risks of serious
adverse events and those of any adverse events. However, due to
the exponentially increased amount of work required for non-ran-
domised studies, we planned to register and perform a new system-
atic review and meta-analysis of non-randomised studies for ad-
verse events, if there was uncertainty in the balance of benefits and
harms of effective treatment(s). We did not perform this because of
the findings of the review.
Types of participants
We included randomised clinical trials with adult participants with
decompensated liver cirrhosis, who are undergoing treatment for
spontaneous bacterial peritonitis (SBP). We excluded randomised
clinical trials in which participants have previously undergone liver
transplantation, have SBP due to other causes, or have secondary
peritonitis (i.e. peritonitis due to hollow viscus perforation or in-
flammation of other intra-abdominal organs, such as appendicitis
or pancreatitis).
Types of interventions
We included any of the following different antibiotic interventions
for comparison with one another, either alone or in combination.
• Cephalosporins
• Penicillins
• Quinolones
• Other classes of antibiotics
We did not include trials evaluating interventions targeted at fluid
and electrolyte balance, or the treatment of shock. However, we in-
cluded trials in which such cointerventions are administered equal-
ly in all the intervention arms.
We evaluated the plausibility of the transitivity assumption (the as-
sumption that participants included in the different trials with dif-
ferent treatments can be considered to be a part of a multiarm ran-
domised clinical trial and could potentially have been randomised
to any of the interventions) (Salanti 2012), by looking at the inclu-
sion and exclusion criteria in the studies. In other words, any partic-
ipant that meets the inclusion criteria is, in principle, equally like-
ly to be randomised to any of the above eligible interventions. This
necessitates that information on potential effect modifiers, such
as the presence of other features of decompensation (hepatorenal
syndrome, hepatic encephalopathy, or variceal bleeding) are the
same across trials. Since, there was no concern about the transi-
tivity assumption, we did not perform a separate meta-analysis for
people with cirrhosis and SBP versus without other features of de-
compensation.
Types of outcome measures
Primary outcomes
• All-cause mortality at maximal follow-up (time to death)
• Health-related quality of life using a validated scale, such as the
EQ-5D or 36-Item Short Form Health Survey (SF-36) (EuroQol
2018; Optum 2018), at maximal follow-up
• Serious adverse events (during or within 6 months after cessa-
tion of the intervention). We defined a serious adverse event as
any event that would increase mortality; is life-threatening; re-
quires hospitalisation; results in persistent or significant disabil-
ity; is a congenital anomaly/birth defect; or any important med-
ical event that might jeopardise the person or require interven-
tion to prevent it (ICH-GCP 1997). However, none of the authors
defined serious adverse events. Therefore, we used the defini-
tions provided by trial authors for serious adverse events (as in-
dicated in the protocol).
* Proportion of participants with one or more serious adverse
event(s)
* Number of serious adverse events per participant
Secondary outcomes
• Any adverse event (during or within 6 months after cessation of
the intervention): we defined an adverse event as any untoward
medical occurrence, not necessarily having a causal relationship
with the intervention, but resulting in a dose reduction or dis-
continuation of intervention (any time after commencement of
the intervention) (ICH-GCP 1997). However, none of the authors
defined 'adverse event'. Therefore, we used the definitions pro-
vided by trial authors for adverse events (as indicated in the pro-
tocol).
* Proportion of participants with one or more adverse event
* Number of any adverse events per participant
• Time to liver transplantation (maximal follow-up)
• Time to resolution of spontaneous bacterial peritonitis (SBP)
(however defined by study authors at maximal follow-up)
* Symptomatic recovery
* Recovery according to definitions used for SBP
• Number of other decompensation episodes (maximal fol-
low-up)
Exploratory outcomes
• Length of hospital stay (all hospital admissions until maximal
follow-up)
• Number of days of lost work (in people who work) (maximal fol-
low-up)
• Treatment costs (including the cost of the treatment and any re-
sulting complications)
We have chosen outcomes based on their importance to patients in
a survey related to research priorities for people with liver diseases
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(Gurusamy 2019), based on feedback of the patient and public rep-
resentative of this project, and based on an online survey about the
outcomes promoted through the Cochrane Consumer Network.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid,
and Science Citation Index Expanded (Web of Science) from in-
ception to 10 November 2018, without applying any language re-
strictions (Royle 2003). We searched for all possible comparisons
formed by the interventions of interest. To identify further ongo-
ing or completed trials, we also searched clinicaltrials.gov, and
the World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/) which included various trial
registers, including ISRCTN and ClinicalTrials.gov on 10 Novem-
ber 2018. We also searched the European Medical Agency (EMA)
(www.ema.europa.eu/ema/), and US Food and Drug Administra-
tion (FDA) registries (www.fda.gov), for randomised clinical trials
on 10 November 2018. The search strategies are provided in Appen-
dix 1.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane Review on antibiotic treatments in liver cirrhosis to iden-
tify additional trials for inclusion (Chavez-Tapia 2009).
Data collection and analysis
Selection of studies
Two review authors (KG and LP) independently identified trials for
inclusion by screening the titles and abstracts, and sought full-text
articles for any references identified by at least one of the review au-
thors for potential inclusion. We selected trials for inclusion based
on the full-text articles. We provided the list of references that we
excluded and the reasons for their exclusion in the 'Characteristics
of excluded studies' table. We also planned to list any ongoing tri-
als identified primarily through the search of the clinical trial regis-
ters for further follow-up. We resolved any discrepancies through
discussion.
Data extraction and management
Two review authors (KG and LP) independently extracted the fol-
lowing data in a piloted Microsoft Excel-based data extraction form
(after translation of non-English articles).
• Outcome data (for each outcome and for each intervention
group whenever applicable)
* number of participants randomised
* number of participants included for the analysis
* number of participants with events for binary outcomes,
mean and standard deviation for continuous outcomes,
number of events and the mean follow-up period for count
outcomes, and number of participants with events and the
mean follow-up period for time-to-event outcomes
* natural logarithm of hazard ratio and its standard error, if this
was reported, rather than the number of participants with
events and the mean follow-up period for time-to-event out-
comes
* definition of outcomes or scale used, if appropriate
• Data on potential effect modifiers
* participant characteristics, such as age, sex, presence of oth-
er features of decompensation (hepatorenal syndrome, he-
patic encephalopathy, and variceal bleeding), the aetiology
for cirrhosis, and the interval between diagnosis of SBP and
treatment
* details of the intervention and control (including dose, fre-
quency, and duration)
* length of follow-up
* information related to 'Risk of bias' assessment (please see
below)
• Other data
* year and language of publication
* country in which the participants were recruited
* year(s) in which the trial was conducted
* inclusion and exclusion criteria
We collected outcomes at maximum follow-up, but also at short-
term (up to 3 months) and medium-term (from 3 months to 5 years),
if applicable.
We attempted to contact the trial authors in the case of unclear
or missing information. If there was any doubt as to whether trials
shared the same participants, completely or partially (by identify-
ing common authors and centres), we planned to contact the tri-
al authors to clarify whether the trial report was duplicated. We re-
solved any differences in opinion through discussion.
Assessment of risk of bias in included studies
We followed the guidance in the Cochrane Handbook for Systemat-
ic Reviews of Interventions (Higgins 2011) to assess the risk of bias
in included trials. Specifically, we assessed sources of bias as de-
fined below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008;
Savović 2012a; Savović 2012b; Savović 2018).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence gener-
ation using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice are adequate if performed by an independent per-
son not otherwise involved in the study. In general, we classified
the risk of bias as low if the method used for allocation conceal-
ment suggested that it was extremely likely that the sequence
was generated randomly (for example, use of interactive voice
response system).
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not ran-
dom. We excluded such quasi-randomised studies.
Allocation concealment
• Low risk of bias: the participant allocations could not have been
foreseen in advance of, or during, enrolment. A central and inde-
pendent randomisation unit controlled allocation. The investi-
gators were unaware of the allocation sequence (e.g. if the allo-
cation sequence was hidden in sequentially numbered, opaque,
and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so that the intervention
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allocations may have been foreseen before, or during, enrol-
ment.
• High risk of bias: it is likely that the investigators who assigned
the participants knew the allocation sequence. We excluded
such quasi-randomised studies.
Blinding of participants and personnel
• Low risk of bias: blinding of participants and key study person-
nel was ensured, and it was unlikely that the blinding could
have been broken; or there was rarely no blinding or incomplete
blinding, but the review authors judged that the outcome was
not likely to be influenced by lack of blinding.
• Unclear risk of bias: insufficient information to permit a judge-
ment of 'low risk' or 'high risk'; or the trial did not address this
outcome.
• High risk of bias: no blinding or incomplete blinding, and the
outcome was likely to be influenced by lack of blinding; or blind-
ing of key study participants and personnel was attempted, but
it was likely that the blinding could have been broken, and the
outcome was likely to be influenced by lack of blinding.
Blinded outcome assessment
• Low risk of bias: blinding of outcome assessment was ensured,
and it was unlikely that the blinding could have been broken;
or rarely no blinding of outcome assessment, but the review au-
thors judged that the outcome measurement was not likely to
be influenced by lack of blinding.
• Unclear risk of bias: insufficient information to permit a judge-
ment of 'low risk' or 'high risk'; or the trial did not address this
outcome.
• High risk of bias: any of the following - no blinding of outcome
assessment, and the outcome measurement was likely to be in-
fluenced by lack of blinding; or blinding of outcome assessment,
but likely that the blinding could have been broken, and the out-
come measurement was likely to be influenced by lack of blind-
ing.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make treatment
effects depart from plausible values. The study used sufficient
methods, such as multiple imputation, to handle missing data.
• Unclear risk of bias: there was insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias on the results.
• High risk of bias: the results were likely to be biased due to miss-
ing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined out-
comes: at least one of the outcomes related to the main rea-
son for treatment of people with SBP, namely, all-cause mor-
tality, resolution of SBP along with adverse events. If the origi-
nal trial protocol was available, the outcomes should have been
those called for in that protocol. If the trial protocol was ob-
tained from a trial registry (e.g. ClinicalTrials.gov), the outcomes
sought should have been those enumerated in the original pro-
tocol if the trial protocol was registered before or at the time that
the trial was begun. If the trial protocol was registered after the
trial was begun, those outcomes will not be considered to be re-
liable.
• Unclear risk of bias: not all predefined, or clinically relevant and
reasonably expected, outcomes were reported fully; or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically relevant
and reasonably expected outcomes were not reported, despite
the fact that data on these outcomes should have been available
and recorded.
Other bias
• Low risk of bias: the trial appeared to be free of other compo-
nents that could put it at risk of bias (e.g. inappropriate control
or dose or administration of control, baseline differences, early
stopping).
• Unclear risk of bias: the trial may or may not have been free of
other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that could
put it at risk of bias (e.g. baseline differences, early stopping).
We considered a trial to be at low risk of bias if we assessed the tri-
al to be at low risk of bias across all listed bias risk domains. Oth-
erwise, we considered trials to be at high risk of bias. At the out-
come level, we classified an outcome to be at low risk of bias if the
allocation sequence generation, allocation concealment, blinding
of participants, healthcare professionals, and outcome assessors,
incomplete outcome data, and selective outcome reporting (at the
outcome level) were at low risk of bias for objective and subjective
outcomes (Savović 2018).
Measures of treatment e:ect
Relative treatment eects
For dichotomous variables (e.g. proportion of participants with se-
rious adverse events or any adverse events), we calculated the odds
ratio (OR) with 95% credible interval (CrI) (or Bayesian confidence
interval) (Severini 1993). For continuous variables (e.g. length of
hospital stay), we calculated the mean difference (MD) with 95% Crl.
We planned to use standardised mean difference (SMD) values with
95% Crl for health-related quality of life if included trials used dif-
ferent scales. We planned to obtain the final scores whenever pos-
sible. For count outcomes (e.g. number of serious adverse events
or number of any adverse events), we calculated the rate ratio with
95% Crl. This assumes that the events are independent of each oth-
er, i.e. if a person has had an event they are not at an increased
risk of further outcomes, which is the assumption in Poisson like-
lihood. For time-to-event data (e.g. all-cause mortality at maximal
follow-up), we calculated hazard ratio (HR) with 95% Crl.
Relative ranking
We estimated the ranking probabilities with 95% CrI for all interven-
tions of being at each possible rank for each intervention. We ob-
tained the surface under the cumulative ranking curve (SUCRA) (cu-
mulative probability), rankogram, and relative ranking table with
CrI for the ranking probabilities (Salanti 2011; Chaimani 2013).
Unit of analysis issues
The unit of analysis was the participant undergoing treatment for
SBP according to the intervention group to which the participant
was randomly assigned.
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Cluster-randomised clinical trials
If we identified any cluster-randomised clinical trials, we planned
to include cluster-randomised clinical trials, provided that the ef-
fect estimate adjusted for cluster correlation was available or if
there was sufficient information available to calculate the design
effect (which would allow us to take clustering into account). We
also planned to assess additional domains of risk of bias for clus-
ter-randomised trials according to guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Cross-over randomised clinical trials
If we identified any cross-over randomised clinical trials, we
planned to include only the outcomes after the period of first in-
tervention because the included treatments could have residual ef-
fects.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the in-
clusion criteria. The codes, we used for analysis, accounted for the
correlation between the effect sizes from trials with more than two
groups.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992); otherwise, we used the data available to us. When
intention-to-treat analysis is not used and the data are not miss-
ing at random (for example, treatment was withdrawn due to ad-
verse events or duration of treatment was shortened because of
lack of response and such participants were excluded from analy-
sis), this can lead to biased results; therefore, we conducted best-
worst case scenario analysis (assuming a good outcome in the in-
tervention group and bad outcome in the control group) and worst-
best case scenario analysis (assuming a bad outcome in the inter-
vention group and good outcome in the control group) as sensitiv-
ity analyses whenever possible for binary and time-to-event out-
comes, where binomial likelihood was used.
For continuous outcomes, we planned to impute the standard de-
viation from P values, according to guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). If the
data were likely to be normally distributed, we planned to use the
median for meta-analysis when the mean was not available; oth-
erwise, we planned to simply provide a median and interquartile
range of the difference in medians. If it was not possible to calculate
the standard deviation from the P value or the confidence intervals,
we planned to impute the standard deviation using the largest stan-
dard deviation in other trials for that outcome. This form of impu-
tation can decrease the weight of the study for calculation of mean
differences and may bias the effect estimate to no effect for calcu-
lation of standardised mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by careful-
ly examining the characteristics and design of included trials. We al-
so planned to assess the presence of clinical heterogeneity by com-
paring effect estimates (please see Subgroup analysis and investi-
gation of heterogeneity) in trial reports of different drug dosages,
presence of other features of decompensation (hepatorenal syn-
drome, hepatic encephalopathy, or variceal bleeding), different ae-
tiologies for cirrhosis (for example, alcohol-related liver disease,
viral liver diseases, autoimmune liver disease), and based on the
cointerventions (for example, both groups receive albumin). Differ-
ent study designs and risk of bias can contribute to methodological
heterogeneity.
We assessed statistical heterogeneity by comparing the results of
the fixed-effect model meta-analysis and the random-effects mod-
el meta-analysis, between-study variance (Tau2, and comparing
this with values reported in the study of the distribution of be-
tween-study heterogeneity) (Turner 2012), and by calculating I2
(Jackson 2014), using Stata/SE 15.1 (if applicable). If we identified
substantial clinical, methodological, or statistical heterogeneity,
we planned to explore and address the heterogeneity in subgroup
analysis (see 'Subgroup analysis and investigation of heterogene-
ity').
Assessment of transitivity across treatment comparisons
We assessed the transitivity assumption by comparing the distri-
bution of the potential effect modifiers (clinical: presence of oth-
er features of decompensation, i.e. hepatorenal syndrome, hepatic
encephalopathy, or variceal bleeding; methodological: risk of bias,
year of randomisation, duration of follow-up) across the different
pairwise comparisons.
Assessment of reporting biases
For the network meta-analysis, we planned to perform a compari-
son-adjusted funnel plot. However, to interpret a comparison-ad-
justed funnel plot, it is necessary to rank the studies in a meaning-
ful way as asymmetry may be due to small sample sizes in new-
er studies (comparing newer treatments with older treatments) or
higher risk of bias in older studies (comparing older treatments
with placebo) (Chaimani 2012). As there was no meaningful way in
which to rank these studies (i.e. there was no specific change in the
risk of bias in the studies, sample size, or the control group used
over time), we judged the reporting bias by the completeness of the
search (Chaimani 2012).
Data synthesis
Methods for indirect and mixed comparisons
We conducted network meta-analyses to compare multiple inter-
ventions simultaneously for each of the primary and secondary out-
comes. Network meta-analysis combines direct evidence within tri-
als and indirect evidence across trials (Mills 2012). We obtained a
network plot to ensure that the trials were connected by interven-
tions using Stata/SE 15.1 (Chaimani 2013). We excluded any trials
that were not connected to the network from the network meta-
analysis, and we reported only the direct pairwise meta-analysis
for such comparisons. We summarised the population and method-
ological characteristics of the trials included in the network meta-
analysis in a table based on pairwise comparisons. We conducted a
Bayesian network meta-analysis using the Markov chain Monte Car-
lo method in OpenBUGS 3.2.3, according to guidance from the Na-
tional Institute for Health and Care Excellence (NICE) Decision Sup-
port Unit (DSU) documents (Dias 2016). We modelled the treatment
contrast (i.e. log odds ratio for binary outcomes, mean difference
or standardised mean difference for continuous outcomes, log rate
ratio for count outcomes, and log hazard ratio for time-to-event
outcomes) for any two interventions ('functional parameters') as a
function of comparisons between each individual intervention and
the reference group ('basic parameters'), using appropriate likeli-
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hood functions and links (Lu 2006). We used binomial likelihood
and logit link for binary outcomes, Poisson likelihood and log link
for count outcomes, binomial likelihood and complementary log-
log link (a semiparametric model which excludes censored individ-
uals from the denominator of 'at risk' individuals at the point when
they are censored), and normal likelihood and identity link for con-
tinuous outcomes. We used 'ceftriaxone' as the reference group as
this was the commonest intervention in the trials included in this
review. We used a fixed-effect model and a random-effects model
for the network meta-analysis. We planned to report both models
for comparison with the reference group in a forest plot, when ap-
plicable. For each pairwise comparison in a table, we reported the
fixed-effect model if the two models reported similar results; oth-
erwise, we planned to report the more conservative model.
We used a hierarchical Bayesian model using three different sets
of initial values to start the simulation-based parameter estima-
tion, employing codes provided by NICE DSU (Dias 2016). We used
a normal distribution with large variance (10,000) for treatment ef-
fect priors (vague or flat priors) centred at no effect. For the ran-
dom-effects model, we used a prior distributed uniformly (limits:
0 to 5) for the between-trial standard deviation and assumed this
variability would be the same across treatment comparisons (Dias
2016). We used a 'burn-in' of 30,000 iterations, checked for conver-
gence (of effect estimates and between-study heterogeneity) visu-
ally (i.e. checked whether the values in different chains mix very
well by visualisation), and ran the models for another 10,000 simu-
lations to obtain effect estimates. If we did not obtain convergence,
we increased the number of simulations for the 'burn-in' and used
the 'thin' and 'over relax' functions to decrease the autocorrela-
tion. If we still did not obtain convergence, we planned to use al-
ternate initial values and priors employing methods suggested by
van Valkenhoef 2012. We estimated the probability that each inter-
vention ranks at each of the possible positions using the NICE DSU
codes (Dias 2016).
Assessment of inconsistency
We assessed inconsistency (statistical evidence of the violation
of transitivity assumption) by fitting both an inconsistency model
and a consistency model. We used inconsistency models employed
in the NICE DSU manual, as we used a common between-study
standard deviation (Dias 2014). In addition, we planned to use
design-by-treatment full interaction model and inconsistency fac-
tor plots to assess inconsistency when applicable (Higgins 2012;
Chaimani 2013). We planned to report inconsistency factor plots
when possible using Stata/SE 15.1. In the presence of inconsisten-
cy, we planned to assess whether the inconsistency was due to
clinical or methodological heterogeneity by performing separate
analyses for each of the different subgroups mentioned in the 'Sub-
group analysis and investigation of heterogeneity' section.
If there was evidence of inconsistency, we planned to identify areas
in the network where substantial inconsistency might be present in
terms of clinical and methodological diversities between trials and,
when appropriate, limit network meta-analysis to a more compat-
ible subset of trials.
Direct comparison
We performed the direct comparisons using the same codes and
the same technical details.
Subgroup analysis and investigation of heterogeneity
We planned to assess the differences in the effect estimates be-
tween the following subgroups and investigate heterogeneity and
inconsistency using meta-regression with the help of the codes pro-
vided in the NICE DSU guidance (Dias 2012a), if we included a suffi-
cient number of trials (when there were at least two trials in at least
two of the subgroups) and when the interaction term could be cal-
culated. We planned to use the following trial-level covariates for
meta-regression.
• Trials at low risk of bias compared to trials at high risk of bias
• The presence of other features of decompensation (hepatorenal
syndrome, hepatic encephalopathy, or variceal bleeding)
• The aetiology for cirrhosis (for example, alcohol-related liver
disease, viral liver diseases, autoimmune liver disease)
• Community acquired or nosocomial SBP
• The interval between the diagnosis of SBP and the start of treat-
ment
• Different types of cointerventions (for example, both groups re-
ceive albumin as the cointervention)
• The period of follow-up (short-term: up to 3 months; medi-
um-term: more than 3 months to 5 years; long-term: more than
5 years)
• The definition used by authors for serious adverse events and
any adverse events compared to other definitions (ICH-GCP
1997)
We planned to calculate a single common interaction term (which
assumes that each relative treatment effect versus a common com-
parator treatment is impacted in the same way by the covariate in
question) when applicable (Dias 2012a). If the 95% Crl of the inter-
action term did not overlap zero, we would have considered this
statistically significant heterogeneity or inconsistency (depending
upon the factor being used as covariate).
Sensitivity analysis
If there were post-randomisation dropouts, we reanalysed the re-
sults using the best-worst case scenario and worst-best case sce-
nario analyses as sensitivity analyses whenever possible. We al-
so planned to perform a sensitivity analysis excluding the trials in
which mean or standard deviation, or both were imputed, and use
the median standard deviation in the trials to impute missing stan-
dard deviations.
Presentation of results
We followed the PRISMA-NMA statement while reporting the results
(Hutton 2015). We presented the effect estimates with 95% CrI for
each pairwise comparison calculated from the direct comparisons
and the network meta-analysis. We originally planned to present
the cumulative probability of the treatment ranks (i.e. the proba-
bility that the intervention is within the top two, the probability
that the intervention is within the top three, etc.) in graphs (SU-
CRA) (Salanti 2011). We plotted the probability that each interven-
tion was best, second best, third best, etc. for each of the different
outcomes (rankograms), which are generally considered more in-
formative (Salanti 2011; Dias 2012b), but we did not present these
because of the sparse data which can lead to misinterpretation of
results due to large uncertainty in the rankings (the CrI was 0 to 1
for all the ranks). We uploaded all the raw data and the codes used
for analysis in The European Organization for Nuclear Research
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open source database (Zenodo) (the link is doi.org/10.5281/zeno-
do.3256132).
Grading of evidence
We presented 'Summary of findings' tables for all the primary
and secondary outcomes (see Primary outcomes; Secondary out-
comes). We followed the approach suggested by Yepes-Nunez and
colleagues (Yepes-Nunez 2019). First, we calculated the direct and
indirect effect estimates (when possible) and 95% Crl using the
node-splitting approach (Dias 2010), that is, calculating the direct
estimate for each comparison by including only trials in which
there was direct comparison of interventions and the indirect es-
timate for each comparison by excluding the trials in which there
was direct comparison of interventions (and ensuring a connect-
ed network). Next, we rated the quality of direct and indirect ef-
fect estimates using GRADE methodology which takes into account
the risk of bias, inconsistency (heterogeneity), directness of evi-
dence (including incoherence, the term used in GRADE methodol-
ogy for inconsistency in network meta-analysis), imprecision, and
publication bias (Guyatt 2011). We then presented the relative and
absolute estimates of the meta-analysis with the best certainty
of evidence (Yepes-Nunez 2019). We also presented the 'Summa-
ry of findings' tables in a second format presenting all the out-
comes for selected interventions (Yepes-Nunez 2019): we selected
the three interventions (cetriaxone, cefotaxime, and ciprofloxacin)
which were compared in most trials.
Recommendations for future research
We provided recommendations for future research regarding the
population, intervention, control, outcomes, period of follow-up,
and study design, based on the uncertainties that we identified
from the existing research.
R E S U L T S
Description of studies
Results of the search
We identified 1322 references through electronic searches of CEN-
TRAL (n = 183), MEDLINE Ovid (n = 501), Embase Ovid (n = 238),
Science Citation Index Expanded (n = 316), ClinicalTrials.gov (n =
35) and WHO Trials register (n = 49). After removing duplicate refer-
ences, there were 1050 references. We excluded 1022 clearly irrel-
evant references through reading titles and abstracts. We did not
identify any additional eligible trial by reference searching or by
searching the European Medicines Agency (EMA) or Food and Drug
Administration (FDA). We retrieved a total of 28 full-text references
for further assessment in detail. We excluded 11 references for the
reasons stated in the Characteristics of excluded studies. Thus, we
included a total of 12 trials described in 17 references (Characteris-
tics of included studies). The reference flow is shown in Figure 2.
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Figure 2.   Study flow diagram.
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Included studies
We included 12 trials (Gomez-Jimenez 1993; Navasa 1996; Figueire-
do 1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli 2006;
Ahmed Ather Ch 2014; Abd-Elsalam 2016; Jindal 2016; Piano 2016;
Yim 2017). A total of 1272 participants were randomised to differ-
ent interventions. The number of participants ranged from 20 to
261. A total of 893 participants from 10 trials provided data for one
or more outcomes (Gomez-Jimenez 1993; Navasa 1996; Figueiredo
1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed
Ather Ch 2014; Jindal 2016; Piano 2016). The mean or median age
in the trials ranged from 42 to 60 years in the trials that reported
this information (Gomez-Jimenez 1993; Navasa 1996; Figueiredo
1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed
Ather Ch 2014; Jindal 2016; Piano 2016). The proportion of females
ranged from 18.3% to 42.1% in the trials that reported this informa-
tion (Gomez-Jimenez 1993; Navasa 1996; Figueiredo 1997; Rastegar
1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 2014;
Jindal 2016; Piano 2016). The most common organism isolated was
Eschericia coli (E coli) (18.6% to 56.7%) in the trials that reported
the isolated micro-organisms (Gomez-Jimenez 1993; Navasa 1996;
Chen 2005; Angeli 2006). The next most common was the Klebsiella
species (5.0% to 5.7%) and Streptococcus pneumoniae (S pneumo-
niae) (1.7% to 9.8%) (Gomez-Jimenez 1993; Navasa 1996); the re-
maining organisms were less frequent.
All trials had short-term follow-up (Gomez-Jimenez 1993; Navasa
1996; Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; An-
geli 2006; Ahmed Ather Ch 2014; Abd-Elsalam 2016; Jindal 2016; Pi-
ano 2016; Yim 2017), ranging from one week to three months.
A total of 13 interventions were compared in the trials. Ceftriax-
one, cefotaxime, and ciprofloxacin were the commonest antibiotics
compared in the trials. The important characteristics, antibiotics
compared, potential effect modifiers, and follow-up in each trial
are reported in Table 1. None of the trials compared antibiotics
with no treatment or placebo. Overall, no systematic differences
between any of the comparisons seemed to exist.
None of the trials reported the proportion of people with other
features of decompensation, such as hepatorenal syndrome and
active variceal bleeding. The proportion of participants with alco-
hol-related cirrhosis ranged between 13.5% to 64.5% in the trials
that reported this information (Gomez-Jimenez 1993; Navasa 1996;
Chen 2005; Angeli 2006; Jindal 2016; Piano 2016). The proportion of
participants with viral-related cirrhosis ranged between 20.6% to
81.1% in the trials that reported this information (Chen 2005; Angeli
2006; Jindal 2016; Piano 2016). None of the trials reported the pro-
portion of people with autoimmune disease-related cirrhosis. The
proportion of participants with other causes for cirrhosis ranged
between 5.4% to 56.9% in the trials that reported this information
(Gomez-Jimenez 1993; Navasa 1996; Chen 2005; Angeli 2006; Jin-
dal 2016; Piano 2016). None of the trials reported the proportion of
people treated for ascites, in addition to antibiotics (for example,
albumin or diuretics).
Funding: the source of funding for two trials was industrial organ-
isations who would benefit from the results of the study (Navasa
1996; Piano 2016); the source of funding for the remaining 10 tri-
als was unclear (Gomez-Jimenez 1993; Figueiredo 1997; Rastegar
1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 2014;
Abd-Elsalam 2016; Jindal 2016; Yim 2017).
Excluded studies
The reasons for exclusion are provided in the 'Characteristics of ex-
cluded studies' tables.
Risk of bias in included studies
The risk of bias is summarised in Figure 3, Figure 4, and in Table
2. As none of the trials were at low risk of bias in all domains, we
considered all trials to be at high risk of bias.
 
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 4.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 4.   (Continued)
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Allocation
Four trials were at low risk of sequence generation bias (Navasa
1996; Angeli 2006; Ahmed Ather Ch 2014; Piano 2016); the remain-
ing eight trials, which did not provide sufficient details, were at
unclear risk of sequence generation bias (Gomez-Jimenez 1993;
Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; Abd-El-
salam 2016; Jindal 2016; Yim 2017).
Three trials were at low risk of allocation concealment bias (Navasa
1996; Angeli 2006; Piano 2016); the remaining nine trials, which
did not provide sufficient details, were at unclear risk of allocation
concealment bias (Gomez-Jimenez 1993; Figueiredo 1997; Raste-
gar 1998; Tuncer 2003; Chen 2005; Ahmed Ather Ch 2014; Abd-El-
salam 2016; Jindal 2016; Yim 2017).
Blinding
None of the trials were at low risk of blinding of patients and health-
care providers' bias; 10 trials were at unclear risk of blinding of
patients and healthcare providers' bias (Navasa 1996; Figueiredo
1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed
Ather Ch 2014; Abd-Elsalam 2016; Piano 2016; Yim 2017); the re-
maining two trials were at high risk of blinding of patients and
healthcare providers' bias (Gomez-Jimenez 1993; Jindal 2016).
None of the trials were at low risk of blinding of outcome asses-
sors' bias; 10 trials were at unclear risk of blinding of outcome as-
sessors' bias (Navasa 1996; Figueiredo 1997; Rastegar 1998; Tuncer
2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 2014; Abd-Elsalam
2016; Piano 2016; Yim 2017); the remaining two trials were at high
risk of blinding of outcome assessors' bias (Gomez-Jimenez 1993;
Jindal 2016).
Incomplete outcome data
Four trials were at low risk of missing outcome bias (Figueiredo
1997; Tuncer 2003; Angeli 2006; Jindal 2016); seven trials were at
unclear risk of missing outcome bias (Gomez-Jimenez 1993; Navasa
1996; Rastegar 1998; Ahmed Ather Ch 2014; Abd-Elsalam 2016; Pi-
ano 2016; Yim 2017), because they either did not state the number
of post-randomisation dropouts or we could not assess whether the
post-randomisation dropouts were related to the intervention and
outcome; the remaining one trial was at high risk of missing out-
come bias, because the post-randomisation dropouts were likely to
be related to the outcome (Chen 2005).
Selective reporting
Six trials were at low risk of selective outcome reporting bias
(Gomez-Jimenez 1993; Navasa 1996; Tuncer 2003; Angeli 2006; Jin-
dal 2016; Piano 2016): although a protocol published prior to re-
cruitment was not available for these trials, these trials reported all-
cause mortality or resolution of SBP along with adverse events; the
remaining six trials were at high risk of selective outcome report-
ing bias (Figueiredo 1997; Rastegar 1998; Chen 2005; Ahmed Ather
Ch 2014; Abd-Elsalam 2016; Yim 2017): a protocol published prior
to recruitment was not available for these trials, and these trials
did not report reasonably expected clinical outcomes which would
have been measured in a trial of this nature.
Other potential sources of bias
There were no other biases in the trials.
E:ects of interventions
See: Summary of findings for the main comparison; Summary of
findings 2
The network plot for all outcomes for which network meta-analysis
was performed is shown in Figure 1. If a network meta-analysis was
not performed, the reason for not performing the network meta-
analysis is reported under the outcome. Only one trial was includ-
ed for each comparison in all outcomes other than resolution of
spontaneous bacterial peritonitis (SBP). Even for resolution of SBP,
where one of the comparisons had two trials, the between-study
standard deviation was the same as the mean of the prior distribu-
tion: the 95% credible intervals (CrIs) of the random-effects model
were not representative. Therefore, we used the fixed-effect mod-
el for all the network meta-analyses and did not present the for-
est plots comparing the fixed-effect and random-effects models. In
addition, the deviance information criteria statistics showed that
model fit was not improved with the random-effects model (Table
3), and the random-effects model did not alter the interpretation
on the effectiveness of treatments. These findings support the use
of the fixed-effect model.
There was no evidence of inconsistency, as indicated by deviance
information criteria. As a consequence of the sparse data (only 1
trial was included for each comparison for most outcomes), we did
not consider the results from the design-by-treatment interaction
model to assess inconsistency. We were unable to obtain inconsis-
tency factor plots in Stata/SE 15.1. This was either because there
was only one closed loop resulting from a single three-arm trial or
because heterogeneity could not be calculated due to the presence
of a single trial for the comparison.
The 95% CrI of the probability ranks were wide and included 0 and
1 in all the comparisons for all the outcomes. This was probably
because of the sparse data from small trials. Therefore, we did not
present the ranking probabilities (in a table), rankograms, and SU-
CRA plots as we considered that presenting this information would
be misleading due to large uncertainty in the rankings.
Certainty of evidence was very low for all the comparisons. This was
because all the trials were at unclear or high risk of bias for two or
more risk of bias domains at the outcome level (downgraded 1 lev-
el), the sample size was small (downgraded 1 level), and the wide
CrIs overlapping significant clinical effect and no effect (downgrad-
ed 1 level). There was no evidence of indirectness or publication
bias. We could not assess inconsistency in the GRADE context (i.e.
heterogeneity) as there was only one trial for each comparison for
most outcomes.
All-cause mortality
Nine trials (653 participants) reported all-cause mortality (Gomez-
Jimenez 1993; Navasa 1996; Figueiredo 1997; Rastegar 1998;
Tuncer 2003; Chen 2005; Angeli 2006; Jindal 2016; Piano 2016). A
total of 13 interventions were compared with each other. There
were nine interventions connected to the network (Figure 1), and
four unconnected interventions. Only one trial was included in each
pairwise comparison. There were no significant differences in the
all-cause mortality between any of the interventions included in
the network meta-analysis (Table 4). There were also no significant
differences in the all-cause mortality between the following com-
parisons which could not be included in the network meta-analysis
because they were not connected.
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• Pefloxacin versus ampicillin plus gentamycin: HR 0.80 (95% CrI
0.02 to 30.66).
• Imipenem versus cefepime: HR 0.98 (95% CrI 0.60 to 1.57).
Health-related quality of life
None of the trials reported health-related quality of life.
Serious adverse events
One trial (31 participants) reported the proportion of participants
with serious adverse events (Piano 2016). It was not clear whether
the authors used the ICH-GCP definition of serious adverse events
(ICH-GCP 1997). There was no significant difference in the propor-
tion of people with serious adverse events between meropenem
plus daptomycin versus ceftazidime: odds ratio (OR) 1.51 (95%
credible interval (CrI) 0.35 to 6.71). None of the trials reported the
number of serious adverse events per participant.
Any adverse event
Five trials (297 participants) reported the proportion of participants
with any adverse event (Gomez-Jimenez 1993; Tuncer 2003; Chen
2005; Angeli 2006; Piano 2016). It was not clear whether the authors
used the ICH-GCP definition of adverse events (ICH-GCP 1997). A to-
tal of seven interventions were compared with each other. All the
interventions were connected (Figure 1). Only one trial compared
each pairwise comparison. The fixed-effect model was used. There
were no significant differences in the proportion of people who de-
veloped any adverse event between any of the interventions (Table
4).
Two trials (291 participants) reported the number of any adverse
events (Angeli 2006; Jindal 2016). It was not clear whether the
authors used the ICH-GCP definition of adverse events (ICH-GCP
1997). The two trials compared two different pairs of interventions.
Therefore, network meta-analysis was not appropriate. There were
no significant differences in the number of adverse events per par-
ticipant in the following comparisons.
• Ceftazdime versus ciprofloxacin: rate ratio 1.39 (95% CrI 0.79 to
2.48).
• Imipenem versus cefepime: rate ratio 1.00 (95% CrI 0.83 to 1.20).
Liver transplantation
One trial (31 participants) reported the proportion of participants
requiring liver transplantation (Piano 2016). There was no signifi-
cant difference in the proportion of people who underwent liver
transplantation between meropenem plus daptomycin versus cef-
tazidime: hazard ratio (HR) 1.77 (95% CrI 0.26 to 15.21).
Resolution of SBP
None of the trials reported resolution of SBP, defined as sympto-
matic recovery from SBP. Nine trials (873 participants) reported re-
covery from SBP, as per definitions used for SBP (Gomez-Jimenez
1993; Navasa 1996; Figueiredo 1997; Tuncer 2003; Chen 2005; Angeli
2006; Ahmed Ather Ch 2014; Jindal 2016; Piano 2016). We compared
a total of 11 interventions with each other. There were eight con-
nected interventions (Figure 1), and 3 unconnected interventions.
Of these, we excluded one comparison because both interventions
in the comparison were unconnected. We excluded one interven-
tion as it was connected to the network solely by one trial in which
all participants had resolution of SBP. We included only one trial
for each pairwise comparison, except for one pairwise comparison.
There were no significant differences in the proportion of people in
whom resolution of SBP could be achieved (Table 4).
There was no significant difference in the resolution of SBP be-
tween imipenem versus cefepime: HR 0.72 (95% CrI 0.45 to 1.12).
We could not obtain convergence for the other comparison involv-
ing cefonicid versus ceftriaxone, in which all 30 participants in the
ceftriaxone group had resolution of SBP and 28/30 (93.3%) of the
cefonicid group had resolution of SBP.
Other features of decompensation
Six trials (535 participants) reported other features of decompen-
sation (Navasa 1996; Tuncer 2003; Chen 2005; Angeli 2006; Jindal
2016; Piano 2016). None of the trials reported the number of people
who developed decompensation; only the number of decompen-
sation events in each group was reported. A total of nine interven-
tions were compared with each other. There were seven connected
interventions (Figure 1), and two unconnected interventions. Only
one trial was included for each pairwise comparison. There were
no significant differences in the number of other decompensation
events between any of the interventions included in the network
meta-analysis (Table 4). There was also no significant difference in
the number of other decompensation events between the uncon-
nected interventions (imipenem versus cefepime): rate ratio 0.97
(95% CrI 0.75 to 1.25).
Length of hospital stay
Two trials (160 participants) reported length of hospital stay
(Navasa 1996; Chen 2005). A total of three interventions were com-
pared with each other. All the interventions were connected (Fig-
ure 1). Only one trial was included in each pairwise comparison.
There were no significant differences in the length of hospital stay
between any of the interventions (Table 4).
Number of work days lost
None of the trials reported this outcome.
Treatment costs
None of the trials reported total treatment costs. Two trials (91 par-
ticipants) reported antibiotic costs for the regimen used (Figueire-
do 1997; Tuncer 2003). The standard deviation of the costs were not
reported and could not be calculated from other data available in
either trial.
In one trial, oral cefixime was compared with intravenous ceftri-
axone (Figueiredo 1997). The non-inflated costs of antibiotic treat-
ment were BRL 62 for the oral cefixime group compared to BRL 2160
for the intravenous ceftriaxone group (Figueiredo 1997). In the sec-
ond trial, oral ciprofloxacin was compared with intravenous cefo-
taxime and intravenous ceftriaxone. The non-inflated costs of an-
tibiotic treatment were USD 6.61 for oral ciprofloxacin, USD 127 for
intravenous cefotaxime, and USD 118 for intravenous ceftriaxone
groups (Tuncer 2003).
Subgroup analysis
We did not perform any of the planned subgroup analysis because
of sparse data in the trials, short follow-up in all trials, and the un-
clear or high risk of bias for each of the outcomes in all trials.
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Sensitivity analysis
The scenario analysis we performed for post-randomisation
dropouts for binary outcomes and time-to-event outcomes (where
binomial likelihood was used). None of these revealed any alter-
ations in the results. We did not impute the standard deviation for
any continuous outcome.
Assessment of reporting biases
We were unable to perform the comparison-adjusted funnel plot
because there was no meaningful way in which to rank the studies
(i.e. there was no specific change in the risk of bias in the studies,
sample size, or the control group used over time).
D I S C U S S I O N
Summary of main results
We performed a systematic review and network meta-analysis of
all the antibiotic treatments for spontaneous bacterial peritoni-
tis (SBP) in people with decompensated liver cirrhosis. We includ-
ed a total of 12 trials, with a total of 1272 participants in this re-
view. In the four trials that reported the isolated organisms, the
most common organism isolated was Eschericia coli (E coli) (18.6%
to 56.7%) (Gomez-Jimenez 1993; Navasa 1996; Chen 2005; Angeli
2006). We compared a total of 13 interventions in these trials. A to-
tal of 10 trials, including 893 participants were included for one or
more outcomes of this review (Gomez-Jimenez 1993; Navasa 1996;
Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli
2006; Ahmed Ather Ch 2014; Jindal 2016; Piano 2016). Only one out-
come, resolution of SBP, featured more than one trial for the same
comparison.
Approximately 75% of participants with SBP had resolution of SBP,
and 25% of participants died from SBP. Overall, there was no evi-
dence of differences for any of the primary or secondary outcomes
of this review. However, it should be noted that the data were
sparse and most of the comparisons involved a single trial. There-
fore, clinically important differences in the outcomes between the
interventions are possible.
Future trials can and should be powered on short-term all-cause
mortality. Based on the probability ranks, it is not clear which in-
terventions should be compared in future trials. Intravenous ceftri-
axone and cefotaxime were the commonest interventions used in
the trials. The sample size required in such trials based on a con-
trol group proportion of 25% (weighted median control group pro-
portion in ceftriaxone in the trials), a relative risk reduction of all-
cause mortality of 20% in the experimental group, type I error of
5%, and type II error of 20% is 2188 participants. In such a trial,
health-related quality of life, and adverse events (due to any cause:
disease-related, treatment-related, or comorbidity-related) should
be assessed as outcomes. A short period of follow-up of 90 days
may be sufficient to determine the effectiveness of an intervention.
Overall completeness and applicability of evidence
The trials included a wide variety of patients with SBP. There did not
seem to be any restriction based on the aetiology or the presence
of other features of decompensation in the trials that provided this
information. Therefore, the results of the study are applicable in all
people with cirrhosis and SBP. We excluded trials in which partici-
pants had undergone liver transplantation. Therefore, the findings
of this review are not applicable in people with liver decompensa-
tion after liver transplantation.
Certainty of the evidence
The overall certainty of evidence was very low. One of the main rea-
sons for the very low-certainty evidence was the unclear or high risk
of bias in many of the trials. It is possible to perform trials at low risk
of bias in the field. To perform a trial at low risk of bias, randomisa-
tion can be performed using standard methods, for example, web-
based central randomisation; blinding can be achieved by using a
double placebo design (i.e. a placebo for intervention and a place-
bo for control); an intention-to-treat analysis can be performed;
and a protocol can be published prior to recruitment. None of these
have any major ethical considerations; therefore, a low risk of bias
trial is very much feasible.
Another major reason for very low-certainty evidence is impreci-
sion: the trials had small sample sizes and the credible intervals
(CrIs) overlapped clinically significant benefits and clinically signif-
icant harms for all comparisons. Therefore, future trials should be
adequately powered with sample sizes, as described in the previ-
ous section.
Heterogeneity could not be measured because of the presence of a
single trial for most comparisons. We used clinical outcomes; there-
fore, there is no issue of indirectness due to outcomes. The direct
comparisons and network meta-analysis results did not result in al-
tered conclusions and the indirect evidence was applicable only in
very few comparisons because of the nature of the network. In the
comparisons for which indirect evidence was available, the effect
estimates were similar to that of direct comparisons. There was no
evidence that the patient selection or methodological differences
were systematically different across comparisons (i.e. there was no
concern regarding the transitivity assumption). Therefore, there is
no concern about indirectness of evidence. There was no meaning-
ful way to rank these studies (i.e. there was no specific change in
the risk of bias in the studies, sample size, or the control group used
over time); we have completed a thorough search for studies on ef-
fectiveness. We found no evidence of publication bias.
Potential biases in the review process
We selected a range of databases to search without using any lan-
guage restrictions and conducted the network meta-analysis ac-
cording to NICE DSU guidance (Dias 2016). In addition, we have
analysed data using the fixed-effect and random-effects model, al-
though we used the fixed-effect model for all the outcomes for the
reasons described above. These are the strengths of the review
process.
We have excluded studies that compared variations in duration or
dose in the different interventions. Hence, this review does not pro-
vide information on whether one variation is better than another.
Another major limitation of this review was the paucity of data. Few
trials were included for each comparison; in many comparisons,
only one trial was included. This makes it difficult to assess whether
the effect estimates are reproducible. This paucity of data decreas-
es the confidence in the results.
All of the network meta-analyses included only sparse data from
trials at high risk of bias. We were able to compare the direct and in-
direct estimates for very few comparisons. However, the potential
effect modifiers in the trials that reported them were broadly simi-
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lar across comparisons. The results of direct comparisons and indi-
rect comparisons were also similar, when applicable. However, one
cannot rule out violation of the transitivity assumption because of
the sparse data; potential differences in the cointerventions, and
potential differences in the definitions used by trial authors for ad-
verse events and serious adverse events.
We included only randomised clinical trials which are known to fo-
cus mostly on benefits and do not collect and report harms in a de-
tailed manner. Therefore, it is possible that we missed a large num-
ber of non-randomised studies addressing the reporting of harms.
A significant effort is required to identify the non-randomised stud-
ies and assess the risk of bias in those studies. Since it is possible to
conduct future studies powered on mortality, a systematic review
on adverse events appears to be unnecessary in a superiority trial
(as a treatment that reduces short-term mortality will be used even
if it increases the adverse events).
Agreements and disagreements with other studies or
reviews
This is the first network meta-analysis on the topic. The on-
ly systematic review on this topic compared third-generation
cephalosporins with other empirical broad-spectrum antibiotics
in patients with nosocomial SBP (Fiore 2018). This study in-
cluded eight non-randomised studies and concluded that there
was higher prevalence of antibiotic resistance to third-generation
cephalosporins than empirical broad-spectrum antibiotics in pa-
tients with nosocomial SBP (Fiore 2018). Only one of the includ-
ed studies in this review included solely people with nosocomi-
al SBP (Piano 2016). There was no evidence of a difference in
any of the outcomes between the meropenem plus daptomycin
versus ceftazidime group in this trial. However, this was a small
trial and included only 31 participants, indicating that clinical-
ly important benefits or harms are possible in this comparison.
Therefore, our conclusions are that there is significant uncertain-
ty about whether broad-spectrum antibiotics (meropenem plus
daptomycin) are better than third-generation cephalosporins (cef-
tazidime) in the treatment of nosocomial SBP.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Short-term mortality after spontaneous bacterial peritonitis (SBP)
is high (around 25%). There is significant uncertainty about which
antibiotic therapy is better in people with SBP. The majority of the
randomised clinical trials used third-generation cephalosporins,
such as intravenous ceftriaxone or cefotaxime as one of the inter-
ventions.
Implications for research
Further well-designed randomised clinical trials are necessary.
Some aspects of the design of the randomised clinical trials should
be as follows.
• Study design
* Placebo-controlled, parallel, randomised clinical trial
• Participants
* People with cirrhosis and SBP
• Intervention
* Not identified from this network meta-analysis. This could be
one of the newer broad-spectrum antibiotics (or combina-
tion of antibiotics) or oral third-generation cephalosporins or
oral ciprofloxacin.
• Control
* Intravenous ceftriaxone or cefotaxime until at least resolu-
tion of SBP or availability of culture results.
• Outcomes
* Primary outcome: short-term mortality (90-day all-cause
mortality)
* Secondary outcomes: health-related quality of life, adverse
events, resolution of SBP, and resource utilisation measures
including length of hospital stay
* Minimum length of follow-up: 90 days
• Sample size: please see Discussion.
Trials need to be conducted and reported according to the SPIRIT
(Standard Protocol Items: Recommendations for Interventional
Trials) statement (Chan 2013), and CONSORT statement (Schulz
2010).
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Characteristics of included studies [ordered by study ID]
 
Methods Randomised clinical trial
Participants Country: Egypt
Number randomised: not stated
Post-randomisation dropouts: not stated
Revised sample size: not stated
Average age: not stated
Females: not stated
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 0.25
Years of recruitment: 2014
Inclusion criteria
• First episode of SBP
Interventions Participants were randomly assigned to two groups
Group 1: cefotaxime (n = not stated)
Further details: cefotaxime 2 gm twice/day (route and duration not stated clearly, but appears to be 5
days or 1 week)
Group 2: ceftriaxone (n = not stated)
Further details: ceftriaxone 2 gm once/day (route duration not stated clearly, but appears to be 5 days
or 1 week)
Total number of participants and number of participants in each group was not reported
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Outcomes None of the outcomes of interest were reported.
Notes Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (re-
porting bias)
High risk Comment: a prepublished protocol was not available, but the authors do not
report routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Abd-Elsalam 2016  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Pakistan
Number randomised: 240
Post-randomisation dropouts: not stated
Revised sample size: 240
Average age: 44 years
Females: 67 (27.9%).
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
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Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 0.25
Years of recruitment: 2011
Exclusion criteria
• Patients with haemorrhagic or malignant ascites
• Secondary peritonitis
• Tuberculosis peritonitis
• Hepatocellular carcinoma
• Diabetes mellitus
Interventions Participants were randomly assigned to two groups
Group 1: ciprofloxacin (n = 120)
Further details: ciprofloxacin 200 mg IV twice/day for 5 days
Group 2: ceftriaxone (n = 120)
Further details: ceftriaxone 1 gm IV twice/day for 5 days
Outcomes Outcomes reported
• Proportion with recovery from SBP
Notes Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomly allocated in two groups using random num-
ber table".
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (re-
porting bias)
High risk Comment: a prepublished protocol was not available, but the authors do not
report routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Ahmed Ather Ch 2014  (Continued)
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Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 116
Post-randomisation dropouts: 0
Revised sample size: 116
Average age: 60 years
Females: 48 (41.4%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: both
Viral-related cirrhosis: both
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): both
Follow-up in months: 3
Years of recruitment: not stated
Exclusion criteria
• Antibiotic treatment including prophylactic treatment with quinolones within 1 month of inclusion
• History of hypersensitivity to quinolones or beta-lactam antibiotics
• Age < 18 years and > 75 years
• Evidence of other bacterial or fungal infections
• Evidence of organic nephropathy
• Presence of shock
• Gastrointestinal bleeding
• Dehydration
• Hepatocellular carcinoma
• Cardiac failure
• Extrahepatic neoplasia
Interventions Participants were randomly assigned to two groups.
Group 1: ceftazidime (n = 55)
Further details: ceftazidime 1 g to 2 g once/day or twice/day depending on creatinine levels for 8 days
Group 2: ciprofloxacin (n = 61)
Further details: ciprofloxacin 200 mg IV once/day or twice/day depending on serum creatinine convert-
ed to oral ciprofloxacin 250 mg twice/day to 500 mg twice/day depending on serum creatinine when
possible for a total of 8 days
Outcomes Outcomes reported
• Mortality
• Any adverse events (number of people)
• Proportion with recovery from SBP
• Other features of decompensation
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Notes Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomisation was performed with sealed envelopes containing
treatment options prepared with random numbers generated by the STATISTI-
CA 6.1 software."
Allocation concealment
(selection bias)
Low risk Quote: "Randomisation was performed with sealed envelopes containing
treatment options prepared with random numbers generated by the STATISTI-
CA 6.1 software."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: a prepublished protocol was not available but the authors report
routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Angeli 2006  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: China
Number randomised: 45
Post-randomisation dropouts: 8
Revised sample size: 37
Average age: 56 years
Females: 9 (24.3%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: both
Viral-related cirrhosis: both
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
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Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 1
Years of recruitment: 2000-2002
Exclusion criteria
• Allergy to penicillins, cephalosporins or aminoglycoside
• Expected life expectancy of less than one month
• Secondary peritonitis or tumour rupture
• Renal impairment
• Antibiotic treatment during previous 2 weeks
Interventions Participants were randomly assigned to two groups.
Group 1: cefotaxime (n = 19)
Further details: cefotaxime 1 g IV three times/day for minimum 5 day
Group 2: amikacin (n = 18)
Further details: amikacin with plasma level maintained at <= 30 mg/dL after a loading dose of 500 mg
or 8 mg/Kg depending on weight for a total duration of minimum 5 days
Outcomes Outcomes reported
• Mortality
• Any adverse event (number of people)
• Proportion with recovery from SBP
• Other features of decompensation
• Length of hospital stay
Notes Attempts were made to contact the authors in December 2018; there were no replies.
Reason for post-randomisation dropouts: other causes of peritonitis, death, discharged against med-
ical advice before starting treatment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: there were post-randomisation dropouts which were related to the
outcomes.
Chen 2005  (Continued)
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Selective reporting (re-
porting bias)
High risk Comment: a prepublished protocol was not available but the authors do not
report routinely measured clinical outcomes adequately
Other bias Low risk Comment: no other bias was noted.
Chen 2005  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Brazil
Number randomised: 38
Post-randomisation dropouts: 0
Revised sample size: 38
Average age: 54 years
Females: 16 (42.1%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): yes
Follow-up in months: 0.25
Years of recruitment: not stated
Exclusion criteria
• Hypersensitivity to cephalosporins
• Secondary bacterial peritonitis
• Severe shock
• Renal failure
• Grade III and IV encephalopathy
• Hypotension
Interventions Participants were randomly assigned to two groups.
Group 1: cefixime (n = 20)
Further details: cefixime 400 mg/day oral until 2 days after resolution of signs/symptoms/polymor-
phonuclear count < 250/mm3
Group 2: ceftriaxone (n = 18)
Further details: ceftriaxone 1g IV twice/day until 2 days after resolution of signs/symptoms/polymor-
phonuclear count < 250/mm3
Outcomes Outcomes reported
• Mortality
• Proportion with recovery from SBP
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• Treatment costs
Notes We were unable to locate the current contact details of the author.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Quote: "Sealed envelope method"
Comment: further details were not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
High risk Comment: prepublished protocol was not available but the authors do not re-
port routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Figueiredo 1997  (Continued)
 
 
Methods Open randomised clinical trial
Participants Country: Spain
Number randomised: 60
Post-randomisation dropouts: not stated
Revised sample size: 60
Average age: 59 years
Females: 13 (21.7%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: both
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
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Treated for ascites in addition to antibiotics (for example albumin or diuretics): not stated
Follow-up in months: 0.5
Years of recruitment: 1987-1990
Exclusion criteria
• History of allergy to beta-lactam antibiotics
• Haemorrhage into ascites
• Pancreatitis
• Tuberculous peritonitis
• Peritoneal carcinomatosis
Interventions Participants were randomly assigned to two groups.
Group 1: cefonicid (n = 30)
Further details: cefonicid 2g IV twice/day for 10 or 4 days after becoming afebrile, whichever was short-
est.
Group 2: ceftriaxone (n = 30)
Further details: ceftriaxone 2g IV once/day for 10 or 4 days after becoming afebrile, whichever was
shortest.
Outcomes Outcomes reported
• Mortality
• Any adverse event (number of people)
• Proportion with recovery from SBP
Notes We were unable to locate the current contact details of the author.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Comment: open clinical trial
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Comment: open clinical trial
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (re-
porting bias)
Low risk Comment: a prepublished protocol was not available but the authors report
routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Gomez-Jimenez 1993  (Continued)
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Methods Open randomised clinical trial
Participants Country: India
Number randomised: 175
Post-randomisation dropouts: 0
Revised sample size: 175
Average age: 49 years
Females: 32 (18.3%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): both
Alcohol-related cirrhosis: both
Viral-related cirrhosis: both
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 3
Years of recruitment: 2012-2014
Inclusion criteria (if at least one of the following conditions is met)
• No response at 48 hours on 3rd generation cephalosporins
• Current or recent (within 3 months) infection with 3rd generation cephalosporin-resistant bacteria
• New onset SBP detected after 48 hours of hospitalisation
Exclusion criteria
• Pregnant females
• Secondary peritonitis
• Tubercular or fungal peritonitis
• Advanced hepatocellular carcinoma
• Human immunodeficiency virus infection
• Patients on immunosuppressive therapy
• Patients who had undergone liver transplantation
Interventions Participants were randomly assigned to two groups.
Group 1: cefepime (n = 88)
Further details: cefepime 2 g IV twice/day for 5 days
Group 2: imipenem (n = 87)
Further details: imipenem 1 g IV three times/day for 5 days
Outcomes Outcomes reported
• Mortality
• Any adverse events (number of events)
• Proportion with recovery from SBP
• Other features of decompensation
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Notes Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Comment: open clinical trial
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Comment: open clinical trial
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: a prepublished protocol was not available but the authors report
routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Jindal 2016  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 132
Post-randomisation dropouts: 9
Revised sample size: 123
Average age: 59 years
Females: 44 (35.8%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): both
Alcohol-related cirrhosis: both
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
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Follow-up in months: 0.5
Years of recruitment: 1992-1994
Exclusion criteria
• Absence of severe complications at infection diagnosis, i.e. shock, gastrointestinal haemorrhage, re-
nal impairment or grade II-IV hepatic encephalopathy
• Antibiotic treatment within 2 weeks before inclusion
• History of hypersensitivity to quinolones or beta-lactam antibiotics
Interventions Participants were randomly assigned to two groups.
Group 1: ofloxacin (n = 64)
Further details: ofloxacin 100 mg/day to 800 mg/day depending upon creatinine levels (4 days to 2
weeks)
Group 2: cefotaxime (n = 59)
Further details: cefotaxime 1 g/day to 8 g/day depending upon creatinine levels (4 days to 2 weeks)
Outcomes Outcomes reported
• Mortality
• Proportion with recovery from SBP
• Other features of decompensation
• Length of hospital stay
Notes We were unable to locate the current contact details of the author.
Reason for post-randomisation dropouts: secondary peritonitis, voluntary dropout
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was performed with sealed envelopes containing the
treatment options prepared with random numbers generated by the SAS sta-
tistical package (SAS Institute Inc., Cary, NC)".
Allocation concealment
(selection bias)
Low risk Quote: "Randomization was performed with sealed envelopes containing the
treatment options prepared with random numbers generated by the SAS sta-
tistical package (SAS Institute Inc., Cary, NC)".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: there were post-randomisation dropouts; it is not clear whether this
was related to treatment and/or outcomes.
Selective reporting (re-
porting bias)
Low risk Comment: a prepublished protocol was not available but the authors report
routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Navasa 1996  (Continued)
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
43
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 32
Post-randomisation dropouts: 1
Revised sample size: 31
Average age: 60 years
Females: 12 (38.7%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: both
Viral-related cirrhosis: both
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 3
Years of recruitment: 2011-2014
Inclusion criteria
• Nosocomial SBP
Exclusion criteria
• Secondary peritonitis
• Onset of infection ≤ 72 hours from hospitalisation
• Abdominal surgery in the previous 4 weeks
• Hepatocellular carcinoma beyond the Milan Criteria
• Congestive heart failure and/or respiratory failure
• Treatment with third-generation cephalosporins, carbapenems or daptomycin at the time of diagno-
sis of SBP
• Isolation of bacteria resistant to third-generation cephalosporins, carbapenems and/or daptomycin
in cultures performed in the previous 7 days
• Allergy to ceftazidime, meropenem and/or daptomycin
Interventions Participants were randomly assigned to two groups.
Group 1: ceftazidime (n = 16)
Further details: ceftazidime 2 g/day to 6 g/day depending on glomerular filtration rate for at least 7
days
Group 2: meropenem + daptomycin (n = 15)
Further details: meropenem 0.5 g to 3 g/day plus daptomycin 3 mg/Kg/day to 6 mg/Kg/day depending
on glomerular filtration rate for at least 7 days
Outcomes Outcomes reported
• Mortality
• Serious adverse events (number of people)
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• Any adverse events (number of people)
• Liver transplantation
• Proportion with recovery from SBP
• Other features of decompensation
Notes Attempts were made to contact the authors in December 2018; there were no replies.
Reason for post-randomisation dropout: secondary peritonitis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was performed using consecutively numbered, com-
puter-generated, sealed, opaque envelopes containing the treatment as-
signed."
Allocation concealment
(selection bias)
Low risk Quote: "Randomization was performed using consecutively numbered, com-
puter-generated, sealed, opaque envelopes containing the treatment as-
signed."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "Independent laboratory examiners, blinded to assigned treatment,
manually assessed the ascitic fluid PMN count".
Comment: it is not clear whether patients and healthcare providers were
blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Independent laboratory examiners, blinded to assigned treatment,
manually assessed the ascitic fluid PMN count".
Comment: it is not clear whether patients and healthcare providers were
blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: there were post-randomisation dropouts; it is not clear whether this
was related to treatment and/or outcomes.
Selective reporting (re-
porting bias)
Low risk Comment: a prepublished protocol was not available but the authors report
routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Piano 2016  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Iran
Number randomised: 20
Post-randomisation dropouts: not stated
Revised sample size: 20
Average age: 42 years
Females: 5 (25%)
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Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: both
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 0.25
Years of recruitment: not stated
Inclusion and exclusion criteria: not stated
Interventions Participants were randomly assigned to two groups.
Group 1: ampicillin + gentamycin (n = 9)
Further details: ampicillin IV 4 g/day plus gentamycin 40 to 60 mg IV three times/day for 10 to 14 days
Group 2: pefloxacin (n = 11)
Further details: pefloxacin 400 mg/36 hours for 7 to 10 days
Outcomes Outcomes reported
• Mortality
Notes We were unable to locate the current contact details of the author.
Follow-up information was not available, but the follow-up was probably until the end of hospitalisa-
tion.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (re-
porting bias)
High risk Comment: a prepublished protocol was not available but the authors do not
report routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Rastegar 1998  (Continued)
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Methods Randomised clinical trial
Participants Country: Turkey
Number randomised: 53
Post-randomisation dropouts: 0
Revised sample size: 53
Average age: 46 years
Females: 19 (35.8%)
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): both
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: both
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: both
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 0.25
Years of recruitment: not stated
Exclusion criteria
• Hypersensitivity to quinolones or cephalosporins
• Recent antibiotic use
• Systemic infections
• Secondary peritonitis
Interventions Participants were randomly assigned to three groups.
Group 1: cirpofloxacin (n = 16)
Further details: ciprofloxacin 500 mg oral twice/day for 5 days
Group 2: cefotaxime (n = 18)
Further details: cefotaxime 2 g IV three times/day for 5 days
Group 3: ceftriaxone (n = 19)
Further details: ceftriaxone 2 g/day IV for 5 days
Outcomes Outcome reported
• Mortality
• Any adverse events ( number of people)
• Proportion with recovery from SBP
• Other features of decompensation
• Treatment costs
Notes Attempts were made to contact the authors in December 2018; there were no replies.
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Follow-up information was not available but the follow-up was probably until the end of hospitalisa-
tion. Although the authors excluded 3 patients from the analysis, these have been included for all out-
comes other than complications and decompensated cirrhosis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: all patients were included in the analysis of mortality and SBP reso-
lution. There were post-randomisation dropouts related to the treatment and
outcome for remaining outcomes; therefore risk of bias is high for these out-
comes.
Selective reporting (re-
porting bias)
Low risk Comment: a prepublished protocol was not available but the authors report
routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.
Tuncer 2003  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: South Korea
Number randomised: 261
Post-randomisation dropouts: not stated
Revised sample size: 261
Average age: not stated
Females: not stated
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or
variceal bleeding): not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
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Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow-up in months: 0.25
Years of recruitment: 2007-2016
Exclusion criteria
• Allergic to third-generation cephalosporins or quinolones
• Antibiotics within 2 weeks
• Open abdominal surgery within 4 weeks
• Evidence of secondary peritonitis, intra-abdominal haemorrhage, pancreatitis, tuberculous peritoni-
tis or peritoneal carcinomatosis
• Hepatocellular carcinoma with portal vein thrombosis
• Pregnant women
• HIV positivity
Interventions Participants were randomly assigned to three groups.
Group 1: ciprofloxacin (n = not stated)
Further details: (route and duration not stated)
Group 2: cefotaxime (n = not stated)
Further details: (route and duration not stated)
Group 3: ceftriaxone (n = not stated)
Further details: (route and duration not stated)
Number of participants in each group not stated
Outcomes None of the outcomes of interest were reported.
Notes Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (re-
porting bias)
High risk Comment: a prepublished protocol was not available but the authors do not
report routinely measured clinical outcomes adequately.
Yim 2017  (Continued)
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Other bias Low risk Comment: no other bias was noted.
Yim 2017  (Continued)
AIH: autoimmune hepatitis
IV: intravenous
PBC: primary biliary cholangitis
PSC: primary sclerosing cholangitis
SBP: spontaneous bacterial peritonitis
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ariza 1991 Only one group was allowed to receive other antibiotics in addition to the randomised treatment.
Badawy 2013 Randomisation was performed after matching to similar patients; the allocation of the second per-
son can be predicted with 100% accuracy.
Felisart 1985 It includes infections other than SBP and no separate data are available.
Grange 2004 It includes infections other than SBP and no separate data are available.
Lim 2011 This is a review.
Liu 2000 This is not a randomised clinical trial.
McCue 1981 This is a review.
Piano 2011 This is a review.
Ricart 2000 It includes infections other than SBP and no separate data are available.
Rimola 1984 This is not a randomised clinical trial.
Taskiran 2004 This is not a randomised clinical trial.
SBP: spontaneous bacterial peritonitis
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised clinical trial
Participants People with cirrhosis and spontaneous bacterial peritonitis
Interventions Oral antibiotics versus intravenous antibiotics
Outcomes Mortality
Notes It was not clear whether a single oral antibiotic was compared with intravenous antibiotic or a
group of oral antibiotics was compared with a group of intravenous antibiotics or whether the
same antibiotic was compared by oral and intravenous antibiotics. We made attempts to clarify
this information from the authors in December 2018, but we did not receive any replies.
Zafar 2018 
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Study
name
In-
ter-
ven-
tion
1
In-
ter-
ven-
tion
2
In-
ter-
ven-
tion
1:
num-
ber
of
par-
tic-
i-
pants
In-
ter-
ven-
tion
2:
num-
ber
of
par-
tic-
i-
pants
Presence of other fea-
tures of decompen-
sation (hepatorenal
syndrome, hepatic
encephalopathy, or
variceal bleeding)
Alcohol-related cir-
rhosis
Viral-related cirrhosis Other causes for cirrhosis Treated
for ascites
in addi-
tion to an-
tibiotics
(e.g. albu-
min or di-
uretics)
Fol-
low-up
in
months
Year
of
re-
cruit-
ment
Abd-
El-
salam
2016
Cefo-
taxime
Cef-
triax-
one
Not
stat-
ed
Not
stat-
ed
Not stated Not stated Not stated Not stated Not stated 0.252014
Tuncer
2003
Cefo-
taxime
Cef-
triax-
one
18 19 Includes people with
and without other fea-
tures of decompensa-
tion
Not stated Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 0.25Not
stat-
ed
Yim
2017
Cefo-
taxime
Cef-
triax-
one
Not
stat-
ed
Not
stat-
ed
Not stated Not stated Not stated Not stated Not stated 0.252007-2016
Ahmed
Ather
Ch
2014
CiprofloxacinCef-
triax-
one
120 120 Not stated Not stated Not stated Not stated Not stated 0.252011
Tuncer
2003
CiprofloxacinCef-
triax-
one
16 19 Includes people with
and without other fea-
tures of decompensa-
tion
Not stated Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 0.25Not
stat-
ed
Yim
2017
CiprofloxacinCef-
triax-
one
Not
stat-
ed
Not
stat-
ed
Not stated Not stated Not stated Not stated Not stated 0.252007-2016
Figueire-
do
1997
Ce-
fixime
Cef-
triax-
one
20 18 Includes people with
and without other fea-
Includes people with
and without alco-
hol-related cirrhosis
Not stated Not stated Not stated 0.25Not
stat-
ed
Table 1.   Characteristics and potential e:ect modifiers of included studies ordered by comparison 
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5
3
tures of decompensa-
tion
Gomez-
Jimenez
1993
Ce-
foni-
cid
Cef-
triax-
one
30 30 Not stated Includes people with
and without alco-
hol-related cirrhosis
Not stated Includes people with and with-
out other causes of cirrhosis
Not stated 0.5 1987-1990
Tuncer
2003
CiprofloxacinCefo-
taxime
16 18 Includes people with
and without other fea-
tures of decompensa-
tion
Not stated Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 0.25Not
stat-
ed
Yim
2017
CiprofloxacinCefo-
taxime
Not
stat-
ed
Not
stat-
ed
Not stated Not stated Not stated Not stated Not stated 0.252007-2016
Chen
2005
AmikacinCefo-
taxime
18 19 Not stated Includes people with
and without alco-
hol-related cirrhosis
Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 1 2000-2002
Navasa
1996
OfloxacinCefo-
taxime
64 59 Includes people with
and without other fea-
tures of decompensa-
tion
Includes people with
and without alco-
hol-related cirrhosis
Not stated Includes people with and with-
out other causes of cirrhosis
Not stated 0.5 1992-1994
An-
geli
2006
Cef-
tazidime
Ciprofloxacin55 61 Not stated Includes people with
and without alco-
hol-related cirrhosis
Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Includes
people re-
ceiving
and not
receiv-
ing oth-
er treat-
ments for
ascites
3 Not
stat-
ed
Pi-
ano
2016
Meropen-
em
plus
dap-
to-
mycin
Cef-
tazidime
15 16 Not stated Includes people with
and without alco-
hol-related cirrhosis
Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 3 2011
to
2014
Raste-
gar
1998
Pe-
floxacin
Ampi-
cillin
plus
11 9 Not stated Not stated Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 0.25Not
stat-
ed
Table 1.   Characteristics and potential e:ect modifiers of included studies ordered by comparison  (Continued)
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5
4
gen-
tamycin
Jin-
dal
2016
Imipen-
em
Ce-
fepime
87 88 Includes people with
and without other fea-
tures of decompensa-
tion
Includes people with
and without alco-
hol-related cirrhosis
Includes people with
and without viral-re-
lated cirrhosis
Includes people with and with-
out other causes of cirrhosis
Not stated 3 2012-2014
Table 1.   Characteristics and potential e:ect modifiers of included studies ordered by comparison  (Continued)
 
 
Study name Intervention 1 Intervention 2 Sequence
genera-
tion
Allocation
conceal-
ment
Blinding of
patients and
healthcare
providers
Blinding of
outcome
assessors
Miss-
ing out-
come
bias
Selec-
tive out-
come
report-
ing
Source of
funding
Abd-Elsalam 2016 Cefotaxime Ceftriaxone Unclear Unclear Unclear Unclear Unclear High Unclear
Tuncer 2003 Cefotaxime Ceftriaxone Unclear Unclear Unclear Unclear Low Low Unclear
Yim 2017 Cefotaxime Ceftriaxone Unclear Unclear Unclear Unclear Unclear High Unclear
Ahmed Ather Ch
2014
Ciprofloxacin Ceftriaxone Low Unclear Unclear Unclear Unclear High Unclear
Tuncer 2003 Ciprofloxacin Ceftriaxone Unclear Unclear Unclear Unclear Low Low Unclear
Yim 2017 Ciprofloxacin Ceftriaxone Unclear Unclear Unclear Unclear Unclear High Unclear
Figueiredo 1997 Cefixime Ceftriaxone Unclear Unclear Unclear Unclear Low High Unclear
Gomez-Jimenez
1993
Cefonicid Ceftriaxone Unclear Unclear High High Unclear Low Unclear
Tuncer 2003 Ciprofloxacin Cefotaxime Unclear Unclear Unclear Unclear Low Low Unclear
Yim 2017 Ciprofloxacin Cefotaxime Unclear Unclear Unclear Unclear Unclear High Unclear
Chen 2005 Amikacin Cefotaxime Unclear Unclear Unclear Unclear High High Unclear
Navasa 1996 Ofloxacin Cefotaxime Low Low Unclear Unclear Unclear Low High
Table 2.   Risk of bias ordered by comparison 
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Angeli 2006 Ceftazidime Ciprofloxacin Low Low Unclear Unclear Low Low Unclear
Piano 2016 Meropenem plus
daptomycin
Ceftazidime Low Low Unclear Unclear Unclear Low High
Rastegar 1998 Pefloxacin Ampicillin plus gen-
tamycin
Unclear Unclear Unclear Unclear Unclear High Unclear
Jindal 2016 Imipenem Cefepime Unclear Unclear High High Low Low Unclear
Table 2.   Risk of bias ordered by comparison  (Continued)
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All-cause mortality at maxi-
mal follow-up
Fixed-effect model Random-effects model Inconsistency model
Dbar 65.76 65.69 65.73
DIC 80.48 80.35 80.43
pD 14.72 14.66 14.7
Adverse events proportion Fixed-effect model Random-effects model Inconsistency model
Dbar 45.75 45.77 45.73
DIC 56.81 56.86 56.79
pD 11.06 11.09 11.06
SBP resolution Fixed-effect model Random-effects model Inconsistency model
Dbar 61.72 62.34 62.42
DIC 75.77 77.07 77.24
pD 14.05 14.73 14.82
Other decompensation Fixed-effect model Random-effects model Inconsistency model
Dbar 56.05 56.01 56.05
DIC 66.88 66.78 66.87
pD 10.83 10.77 10.83
       
Length of hospital stay Fixed-effect model Random-effects model Inconsistency model
Dbar 14.39 14.38 14.39
DIC 18.39 18.36 18.39
pD 3.999 3.986 3.999
Table 3.   Model fit 
Abbreviations
Dbar: posterior mean of deviance; pD: effective number of parameters or leverage; DIC: deviance information criteria
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All-cause mortali-
ty
Ceftriaxone Cefotaxime Ciprofloxacin Ceftazidime Amikacin Ce-
fixime
Cefoni-
cid
Meropen-
em +
dapto-
mycin
Ofloxacin
Ceftriaxone - 0.58[0.11,2.54] 0.63[0.12,2.88] - - 1.26[0.27,7.01]1.29[0.53,3.23]- -
Cefotaxime 0.56[0.11,2.28] - 1.13[0.20,6.67] - 1.40[0.36,5.85] - - - 1.01[0.44,2.36]
Ciprofloxacin 0.65[0.12,2.72] 1.16[0.20,6.90] - 1.76[0.72,4.66] - - - - -
Ceftazidime 1.15[0.17,6.37] 2.08[0.28,15.24] 1.77[0.73,4.58] - - - - 0.56[0.10,2.47]-
Amikacin 0.76[0.09,5.90] 1.39[0.35,6.00] 1.20[0.13,11.68] 0.67[0.06,7.62] - - - - -
Cefixime 1.26[0.26,6.90] 2.32[0.27,23.93] 1.99[0.23,21.07] 1.11[0.11,13.68] 1.66[0.12,25.20]- - - -
Cefonicid 1.30[0.52,3.24] 2.34[0.43,15.52] 2.02[0.36,13.61] 1.14[0.16,9.30] 1.68[0.18,17.44]1.02[0.15,6.39]- - -
Meropenem + dap-
tomycin
0.64[0.05,6.13] 1.16[0.09,13.48] 1.00[0.15,5.60] 0.57[0.11,2.41] 0.83[0.04,13.94]0.50[0.03,7.76]0.49[0.03,5.81]- -
Ofloxacin 0.56[0.09,2.93] 1.01[0.44,2.35] 0.87[0.12,6.19] 0.49[0.06,4.25] 0.73[0.14,3.63] 0.43[0.04,4.34]0.43[0.05,2.87]0.87[0.06,12.52]-
Proportion of peo-
ple with any ad-
verse event
Ceftriaxone Cefotaxime Ciprofloxacin Ceftazidime Amikacin Cefoni-
cid
Meropen-
em +
dapto-
mycin
Ceftriaxone - 0.65[0.14,2.69] 1.03[0.25,4.33] - - 1.00[0.10,10.23]-
Cefotaxime 0.64[0.15,2.62] - 1.60[0.36,7.38] - 1.07[0.10,11.19]- -
Ciprofloxacin 1.02[0.24,4.16] 1.59[0.36,7.46] - 1.95[0.86,4.49] - - -
Ceftazidime 1.97[0.38,10.18] 3.06[0.56,17.74] 1.93[0.87,4.47] - - - 0.61[0.10,3.56]
Amikacin 0.69[0.04,10.94] 1.07[0.10,11.31] 0.66[0.04,10.95] 0.34[0.02,6.58] - - -
Cefonicid 1.00[0.10,10.16] 1.58[0.10,24.34] 0.98[0.06,14.86] 0.51[0.03,8.72] 1.47[0.04,54.82]- -
-
Table 4.   E:ect estimates (network meta-analysis) 
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Meropenem + dap-
tomycin
1.20[0.10,13.53] 1.88[0.15,22.83] 1.17[0.16,8.47] 0.61[0.09,3.62] 1.72[0.06,52.67]1.18[0.04,34.61]-
Resolution of SBP Ceftriaxone Cefotaxime Ciprofloxacin Ceftazidime Amikacin Ce-
fixime
Meropen-
em +
dapto-
mycin
Ofloxacin
Ceftriaxone - 0.95[0.41,2.15] 0.93[0.69,1.25] - - 0.78[0.32,1.88]- -
Cefotaxime 0.90[0.42,1.86] - 1.08[0.45,2.53] - 0.59[0.25,1.34] - - 1.23[0.75,2.06]
Ciprofloxacin 0.93[0.69,1.25] 1.03[0.50,2.24] - 1.05[0.64,1.72] - - - -
Ceftazidime 0.97[0.55,1.72] 1.08[0.44,2.71] 1.05[0.64,1.72] - - - 1.32[0.51,3.46]-
Amikacin 0.54[0.17,1.62] 0.60[0.25,1.38] 0.58[0.18,1.78] 0.55[0.16,1.86] - - - -
Cefixime 0.78[0.32,1.90] 0.87[0.28,2.76] 0.85[0.33,2.14] 0.80[0.28,2.31] 1.47[0.35,6.11] - - -
Meropenem + dap-
tomycin
1.29[0.43,3.92] 1.43[0.39,5.38] 1.38[0.48,4.08] 1.32[0.52,3.51] 2.40[0.51,11.53]1.64[0.40,6.83]- -
Ofloxacin 1.12[0.45,2.70] 1.24[0.76,2.06] 1.21[0.48,2.92] 1.15[0.41,3.23] 2.08[0.79,5.66] 1.43[0.40,5.03]0.87[0.21,3.53]-
-
Other decompen-
sation
Ceftriaxone Cefotaxime Ciprofloxacin Ceftazidime Amikacin Meropen-
em +
dapto-
mycin
Ofloxacin
Ceftriaxone - 1.21[0.43,3.48] 1.01[0.31,3.13] - - - -
Cefotaxime 1.22[0.43,3.53] - 0.82[0.26,2.40] - 1.05[0.11,10.05]- 0.92[0.43,1.95]
Ciprofloxacin 1.01[0.32,3.16] 0.83[0.27,2.46] - 1.40[0.78,2.51] - - -
Ceftazidime 1.43[0.40,5.19] 1.18[0.33,3.97] 1.42[0.81,2.50] - - 1.52[0.72,3.32]-
Amikacin 1.28[0.11,15.66] 1.05[0.11,10.27] 1.27[0.10,15.24] 0.89[0.07,11.72] - - -
Meropenem + dap-
tomycin
2.19[0.49,9.49] 1.81[0.41,7.57] 2.17[0.85,5.64] 1.53[0.73,3.31] 1.72[0.12,24.31]- -
-
Table 4.   E:ect estimates (network meta-analysis)  (Continued)
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Ofloxacin 1.12[0.31,4.09] 0.92[0.43,1.96] 1.10[0.30,4.24] 0.78[0.19,3.35] 0.88[0.08,9.51] 0.51[0.10,2.63]-
Length of hospital
stay
Cefotaxime Amikacin Ofloxacin
Cefotaxime - 1.01[-4.47,6.41] -0.99[-4.07,2.09]
Amikacin 1.01[-4.43,6.47] - -
Ofloxacin -0.99[-4.02,2.02] -2.03[-8.30,4.25] -
-
Table 4.   E:ect estimates (network meta-analysis)  (Continued)
Abbreviations: SBP: spontaneous bacterial peritonitis
The table provides the effect estimates (proportion of people with any adverse events; hazard ratio for all-cause mortality and spontaneous resolution for SBP; rate ratio for
other decompensation; and mean difference in days for length of hospital stay) of each pairwise comparison for the different outcomes. The top half of the table indicates the
effect estimates from the direct comparisons. The bottom half of the table indicates the effect estimates from the network meta-analysis. For network meta-analysis, to identify
the effect estimate of a comparison, say A versus B, look at the cell that occupies the row corresponding to intervention A and the column corresponding to intervention B for
the direct effect estimate. If that cell is empty (indicated by a '-'), look at the row corresponding to intervention B and the column corresponding to intervention A. Take the
inverse of this number (i.e. 1/number) to arrive at the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies the column
corresponding to intervention A and the row corresponding to intervention B for the direct effect estimate. If that cell is empty, look at the column corresponding to intervention
B and the row corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus B. If the cell corresponding to B versus A is also missing
in direct comparisons, this means that there was no direct comparison.
There were no significant differences in the effect estimates for any of the comparisons in any of the outcomes for which network meta-analysis could be performed.
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A P P E N D I C E S
Appendix 1. Search strategies
 
Database Time span Search strategy
Central Register of
Controlled Trials
(CENTRAL) in the
Cochrane Library
Issue 11, 2018 #1 (spontaneous near/3 bacterial near/3 peritonitis)
#2 MeSH descriptor: [Liver Cirrhosis] explode all trees
#3 ((hepatic or liver) and (fibrosis or cirrhosis or cirrhotic))
#4 #2 or #3
#5 #1 and #4
MEDLINE Ovid January 1947 to
November 2018
1. (spontaneous adj3 bacterial adj3 peritonitis).ti,ab.
2. exp Liver Cirrhosis/
3. ((hepatic or liver) and (fibrosis or cirrhosis or cirrhotic)).ti,ab.
4. 2 or 3
5. 1 and 4
6. randomized controlled trial.pt.
7. controlled clinical trial.pt.
8. randomized.ab.
9. placebo.ab.
10. drug therapy.fs.
11. randomly.ab.
12. trial.ab.
13. groups.ab.
14. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. exp animals/ not humans.sh.
16. 14 not 15
17. 5 and 16
Embase Ovid January 1974 to
November 2018
1. exp bacterial peritonitis/
2. (spontaneous adj3 bacterial adj3 peritonitis).ti,ab.
3. 1 or 2
4. exp liver cirrhosis/
5. ((hepatic or liver) and (fibrosis or cirrhosis or cirrhotic)).ti,ab.
6. 4 or 5
7. 3 and 6
 
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
60
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
8. exp crossover-procedure/ or exp double-blind procedure/ or exp randomized con-
trolled trial/ or single-blind procedure/
9. (((((random* or factorial* or crossover* or cross over* or cross-over* or placebo* or
double*) adj blind*) or single*) adj blind*) or assign* or allocat* or volunteer*).af.
10. 8 or 9
11. 7 and 10
Science Citation In-
dex Expanded (Web
of Science)
January 1945 to
November 2018
#1 TS=(spontaneous near/3 bacterial near/3 peritonitis)
#2 TS=((hepatic or liver) and (fibrosis or cirrhosis or cirrhotic))
#3 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-
analysis OR systematic review* OR meta-analys*)
#4 #1 AND #2 AND #3
World Health Or-
ganization Interna-
tional Clinical Tri-
als Registry Platform
(apps.who.int/tri-
alsearch/Default.as-
px)
November 2018 spontaneous bacterial peritonitis
ClinicalTrials.gov November 2018 cirrhosis | Interventional Studies | Spontaneous Bacterial Peritonitis | Phase 2, 3, 4
European Medical
Agency (www.e-
ma.europa.eu/ema/)
and US Food and
Drug Administration
(www.fda.gov)
November 2018 spontaneous bacterial peritonitis
  (Continued)
 
C O N T R I B U T I O N S   O F   A U T H O R S
Protocol
Conceiving the protocol: KG
Designing the protocol: KG
Co-ordinating the protocol: KG
Designing search strategies: KG
Writing the protocol: KG
Providing general advice on the protocol: ET, PW
Securing funding for the protocol: KG
Performing previous work that was the foundation of the current study: not applicable
Review
Co-ordinating the review: KG
Study selection: KG, LP, AB, MP, DR
Data extraction: KG, LP
Writing the review: KG with contribution of LP for characteristics and 'Risk of bias' tables
Providing advice on the review: EJM, PW, AJS, NJC, NH, SF, DT, CSP, BRD, ET
Securing funding for the review: KG
D E C L A R A T I O N S   O F   I N T E R E S T
None known for any of the authors.
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Internal sources
• University College London, UK.
Writing equipment, software, etc.
External sources
• National Institute for Health Research, UK.
Payment for writing reviews, writing equipment, software
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. We did not perform Trial Sequential Analysis (TSA), as the risk of false positive results with Bayesian meta-analysis is probably less or
at least equivalent to TSA.
2. We used the latest guidance from the GRADE Working group (Yepes-Nunez 2019), rather than the previous guidance (Puhan 2014), for
presenting the 'Summary of findings' table.
3. The trials did not report the proportion of people with other episodes of decompensation but reported the number of episodes of
decompensation. Therefore, we treated this as a count outcome and used the Poisson likelihood to calculate the rate ratio.
4. We used ceftriaxone rather than cefotaxime as the control group, since ceftriaxone was the commonest control group in the trials.
5. In the absence of a protocol published prior to the start of the study, we have classified the risk of bias as low for selective reporting bias
only when mortality, adverse events, and spontaneous bacterial peritonitis (SBP) were reported, as we anticipated these outcomes to
be routinely measured in clinical trials of this nature.
6. We used 30,000 iterations as a minimum for burn-in.
7. We did not present some information because of the concern about the misinterpretation of the results. We have highlighted this clearly
within the text of the review along with the reasons for not presenting them.
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